Thiol-ene-based polymerizable composition

Abstract

The present invention refers to the use of compounds comprising, per molecule, at least one polymerizable CC double bond, at least one adhesion-providing moiety, and one at least bivalent hydrocarbon moiety in between as a spacer as primers in a thiolene-based polymerizable composition for improving the adhesion of the composition on a substrate to be coated therewith, wherein the composition further comprises a radical initiator, monomers with at least two polymerizable CC double bonds per molecule, and polythiols with at least two SH groups per molecule, wherein the primers comprise 5-norbornen-2-yl groups as polymerizable CC double bonds, characterized in that compounds are used as primers in the polymerizable composition that a) comprise phosphonic acid groups as adhesion-providing moieties; or b) comprise groups selected from phosphonic acid groups and 3,4-dihydroxyphenyl groups as adhesion-providing moieties, and the polymerizable composition is used as bone adhesive; as well as to corresponding thiol-ene-based compositions; corresponding norbornene derivatives suitable for this purpose; and specific synthesized representatives of such norbornene derivatives.

Claims

1. A use of compounds comprising, per molecule, at least one polymerizable CC double bond, at least one adhesion-providing moiety, and one at least bivalent hydrocarbon moiety in between as a spacer as primers in a thiol-ene-based polymerizable composition for improving the adhesion of the composition on a substrate to be coated therewith, wherein the composition further comprises a radical initiator, monomers with at least two polymerizable CC double bonds per molecule, and polythiols with at least two SH groups per molecule, wherein the primers comprise 5-norbornen-2-yl groups as polymerizable CC double bonds, characterized in that compounds are used as primers in the polymerizable composition that a) comprise phosphonic acid groups as adhesion-providing moieties; or b) comprise groups selected from phosphonic acid groups and 3,4-dihydroxyphenyl groups as adhesion-providing moieties, and that the polymerizable composition is used as a bone adhesive.

2. The use according to claim 1, characterized in that the primers each comprise at least two 5-norbornen-2-yl groups and/or at least two adhesion-providing moieties.

3. The use according to claim 1 or 2, characterized in that the spacer moiety of the primers has a chain length of at least 3 or at least 6 carbon atoms.

4. The use according to claim 1, characterized in that the spacer moiety of the primer has a chain length of not more than 12 or not more than 10 carbon atoms.

5. The use according to claim 1, characterized in that the monomers are selected from compounds with at least two allyl or vinyl ester groups.

6. The use according to claim 5, characterized in that the monomers comprise 1,3,3-triallyl-1,3,5-triazin-2,4,6-trione (TATATO).

7. The use according to claim 1, characterized in that the polythiols are selected from compounds with at least three SH groups per molecule.

8. The use according to claim 7, characterized in that the polythiols comprise tris[2-(3-mercaptopropionyloxy)ethyl]isocyanurate (TEMPIC).

9. The use according to claim 1, characterized in that the composition is a one-component composition.

10. The use according to claim 1, characterized in that the composition is a two-component composition, of which only the first component comprises the primers.

11. The use according to claim 1, characterized in that the composition comprises approximately 0.1 wt % to approximately 5 wt % of a radical initiator, approximately 10 wt % to approximately 50 wt % of monomers, approximately 40 wt % to approximately 80 wt % of polythiols, and approximately 5 wt % to approximately 25 wt % of primers, in such amounts that the sum is 100 wt %.

12. The use according to claim 9, characterized in that the composition contains approximately 0.5 wt % to approximately 2 wt % of a radical initiator, approximately 40 wt % to approximately 60 wt % of monomers, approximately 60 wt % to approximately 80 wt % of polythiols, and approximately 10 wt % to approximately 20 wt % of primers, in such amounts that the sum is 100 wt %.

13. The use according to claim 1, characterized in that the radical initiator is a radical photoinitiator and the composition is photopolymerizable.

14. The use according to claim 9, characterized in that the radical initiator is a radical photoinitiator and the composition is photopolymerizable and the composition is appliable to the substrate to be coated in one step and then curable by irradiation.

15. A norbornene derivative of the following formula ##STR00060## wherein Norb represents a 5-norbornen-2-yl radical; each AM independently represents a phosphonic acid group (HO).sub.2P(?O) or a 3,4-dihydroxyphenyl groups; n and m each independently represent an integer ?1; and Sp represents a spacer group selected from (n+m)-valent hydrocarbon residues with 1 to 40 carbon atoms; provided that at least one of n and m represents an integer >1 when AM represents a 3,4-dihydroxyphenyl group.

16. The norbornene derivative according to claim 15, characterized in that a) one or both of n and m represent(s) 2; and/or b) S represents an (n+m)-valent hydrocarbon residue with 3 to 20 or 6 to 16 carbon atoms, one or more of which are optionally replaced by a heteroatom selected form O, S and N; and/or c) AM represents a phosphonic acid group (HO)2P(?O).

17. The norbornene derivative according to claim 15, characterized in that it is selected from the following compounds: N-(4-hydroxy-4,4-diphosphonobutyl)-5-norbornene-2-carboxylic acid amide sodium salt (N-(4-hydroxy-4,4-diphosphonobutyl)alendronic acid amide sodium salt) (Alendronate-Norb) (E1): ##STR00061## 5-norbornen-2-ylcarbonyloxymethylphosphonic acid (Phn-1C-Norb) (E3): ##STR00062## 6-(5-norbornen-2-ylcarbonyloxy)hexylphosphonic acid (Phn-6C-Norb) (E4): ##STR00063## 6-(2,3-bis(5-norbornen-2-ylcarbonyloxy)propylthio)hexylphosphonic acid (Phn-6C-bisNorb) (E5): ##STR00064## 6-(2,3-bis(5-norbornen-2-ylcarbonyloxy)propylthio)hexane-1,1-diyl-bis(phosphonic acid) (bisPhn-6C-bisNorb) (E6): ##STR00065## 3-(3-(3,4-dihydroxyphenyl)propylthio)propane-1,2-diyl-bis(norbornen-2-carboxylate) (Catechol-3C-bisNorb) (E7): ##STR00066## ethylenediaminetetraacetic acid-bis(2-(3,4-dihydroxyphenyl)ethyl)amide-bis(2-(5-norbornen-2-yl)ethyl)amide (bisCatechol-EDTA-bisNorb) (E8): ##STR00067## and diethylenetriaminepentaacetic acid-bis(2-(5-norbornen-2-yl)ethyl)amide-tris(2-(3,4-dihydroxyphenyl)ethyl)amide (triCatechol-DTPA-bisNorb) (E9): ##STR00068##

18. The use according to claim 1, characterized in that the primer used is a norbornene derivative of the following formula ##STR00069## wherein Norb represents a 5-norbornen-2-yl radical; each AM independently represents a phosphonic acid group (HO).sub.2P(?O) or a 3,4-dihydroxyphenyl groups; n and m each independently represent an integer ?1; and Sp represents a spacer group selected from (n+m)-valent hydrocarbon residues with 1 to 40 carbon atoms; provided that at least one of n and m represents an integer >1 when AM represents a 3,4-dihydroxyphenyl group.

Description

SHORT DESCRIPTION OF THE DRAWINGS

[0057] Below, the present invention will be described in further detail based on specific synthesis, embodiment and comparative examples, which are exclusively for illustrative purposes and not to be understood as limiting, as well as with reference to the attached figures. Of these, FIGS. 1 to 7 are graphic representations of the results of shear bond strength measurements that were achieved with two-component compositions of Examples 1 to 24 and Comparative Examples 1 to 18, and FIGS. 8 to 12 are representations of the results achieved with one-component compositions of Examples 25 to 36 and Comparative Examples 19 to 30.

EXAMPLES

[0058] Unless otherwise specified herein, all reagents reacted in the reactions below were obtained from commercial sources in synthesis grade and used without any further purification. The purity of all intermediates and products obtained in the examples was examined by determining physical data such as melting point (Fp.) and refractive index (RI), as well as by nuclear resonance spectra (1H, 13C and .sup.31P NMR), high-resolution mass spectrometry (HR-MS), and elementary analyses. All norbornenyl-containing compounds were racemic mixtures of the respective endo- and exo-isomers.

[0059] The following synthesis examples are grouped depending on the polymerizable groups PG and adhesion motifs AM that were introduced.

SYNTHESIS EXAMPLES

Synthesis Examples 1 to 8Preparation of Comparative Primers with Allyloxy (Allo) or Allyloxycarbonyloxy (Allcarb) as Pg and Phosphonic Acid (Phn) as am

Synthesis Example 1Preparation of ((2,2-bis(allyloxymethyl)propaneamido)methyl)phosphonic acid (BAPA.SUP.Phn.) (S1)

Step 1: Preparation of 2,2-bis(allyloxymethyl)propanoic acid (BAPA)

[0060] ##STR00010##

[0061] The synthesis known from literature was carried out as described in Antoni et al., Macromolecules 43, 6625-6631 (2010) by reacting 2,2-bis(hydroxymethyl)propanoic acid with allylbromide.

[0062] DC (PE:EE, 9:1) R.sub.f=0.3; RI n.sub.D.sup.20? C.: 1.4566; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.00-5.77 (m, 2H, 2?CH?CH.sub.2), 5.22 (dd, 4H, 2?CH?CH.sub.2), 4.01 (d, .sup.3J.sub.HH=5.5, 1.5 Hz, 4H, 2?OCH.sub.2CH), 3.58 (s, 4H, 2?CCH.sub.2O): 1.25 (s, 3H, CCH.sub.3); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 180.14 (s, COOH), 136.7 (s, CH?CH.sub.2), 117.08 (s, CH?CH.sub.2), 72.55 (s, CCH.sub.2O), 72.01 (s, OCH.sub.2CH), 48.24 (s, C.sub.q), 17.97 (s, CCH.sub.3).

Step 2Preparation of ((2,2-bis(allyloxymethyl)propaneamido)methyl)phosphonic acid (BAPA.SUP.Phn.) (S1)

[0063] ##STR00011##

[0064] The synthesis known from literature was carried out as described in Granskog et al., v.s., by activating BAPA with carbonyldiimidazole (CDI), followed by reacting the mixed anhydride obtained as an intermediate product with aminoethyl phosphonic acid diethyl ester and final ester cleavage with bromotrimethylsilane.

[0065] .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.02-5.73 (m, 2H, 2?CH?CH.sub.2), 5.35-5.08 (m, 4H, 2?CH?CH.sub.2), 4.01 (m, 4H, 2?CH.sub.2CH?CH.sub.2), 3.72-3.64 (m, 2H, NHCH.sub.2P), 3.55 (s, 4H, 2?CCH.sub.2O), 1.19 (s, 3H, CCH.sub.3); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 134.34 (s, CH?CH.sub.2), 117.70 (s, CH?CH.sub.2), 73.28 (s, CCH.sub.2O), 72.62 (s, 2?CH.sub.2CH?CH.sub.2), 47.79 (s, C.sub.q), 34.56 (d, .sup.1J.sub.CP=155.3 Hz, NHCH.sub.2P), 18.38 (s, C.sub.qCH.sub.3); .sup.31P NMR (101 MHZ, CDCl.sub.3) ? (ppm): 19.22.

Synthesis Example 2Preparation of ((((2,2-bis(allyloxymethyl)propanamido)ethyl)azanediyl)-bis(methylene))-bis(phosphonic acid) (BAPA.SUP.bisPhn.) (S2)

[0066] ##STR00012##

[0067] The synthesis known from literature was also carried out according to Granskog et al., v.s., again by first activating the BAPA obtained in the Synthesis Example, Step 1, BAPA with carbonyldiimidazole (CDI), reacting the mixed anhydride with ethylene diamine to obtain aminoethylamide, which was reacted with 2 mol p-formaldehyde and dimethyl phosphite to obtain bis(phosphonic acid dimethyl ester), and again followed by a final ester cleavage with bromotrimethylsilane.

[0068] .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 8.10 (s, 1H, NHCO), 6.12-5.81 (m, 2H, CH?CH.sub.2), 5.21 (m, 4H, 2?CH?CH.sub.2), 3.97 (d, 4H, .sup.3J.sub.HH=12.9 Hz, 2?CH.sub.2CH?CH.sub.2), 3.80 (d, .sup.3J.sub.HH=8.2 Hz, 4H, 2?NCH.sub.2P), 3.70 (m, 4H, NHCH.sub.2CH.sub.2N), 3.54 (m, 4H, 2?CCH.sub.2O), 1.21 (s, 3H, CCH.sub.3); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 178.9 (s, C?O), 136.2 (s, CH?CH.sub.2), 117.40 (s, CH?CH.sub.2), 73.80 (s, CCH.sub.2O), 72.89 (s, 2?CH.sub.2CH?CH.sub.2), 59.4 (s, NHCH.sub.2CH.sub.2N), 52.9+51.5 (s, 2?NCH.sub.2P), 48.98 (s, C.sub.q), 36.71 (s, NHCH.sub.2CH.sub.2N), 18.29 (s, C.sub.qCH.sub.3); .sup.31P NMR (101 MHZ, CDCl.sub.3) ? (ppm): 9.66.

Synthesis Example 3Preparation of Allyloxymethylphosphonic Acid (Phn-1C-Allo) (S3)

Step 1: Preparation of Allyloxymethylphosphonic Acid Diethylester (PhnEt-1C-Allo)

[0069] ##STR00013##

[0070] In a three-necked flask, sodium hydride (1.9 ?qu., 0.7 g, 28.5 mmol) was suspended in 40 ml of dry tetrahydrofuran (THF) under argon. Hydroxymethylphosphonic acid diethylester (PhnEt-1COH) (1 eq., 2.2 ml, 15 mmol) was diluted in 10 ml of THF and slowly added at 0? C. via a septum. After 1 h, allylbromide (1.3 eq., 1.7 ml, 19.5 mmol) was injected into the flask. Then, the ice bath was removed, and the reaction mixture was stirred over night at room temperature. After evaporation of the solvent and non-reacted educts, the raw material was purified by column chromatography (ethyl acetate, EE), 1.85 g (59% of theory) of the desired phosphonates PhnEt-1C-Allo were isolated as a colorless liquid.

[0071] DC (EE) R.sub.f=0.52; RI n.sub.D.sup.20? C.: 1.4357; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 5.96-5.77 (m, 1H, CH.sub.2CH?CH.sub.2), 5.33-5.18 (m, 2H, CH.sub.2CH?CH.sub.2), 4.25-4.03 (m, 6H, 2?OCH.sub.2CH.sub.3, CH.sub.2CH?CH.sub.2), 3.75 (d, .sup.3J.sub.HH=8.7 Hz, 2H, PCH.sub.2O), 1.39-1.29 (t, .sup.3J.sub.HH=7.0 Hz, 6H, 2?OCH.sub.2CH.sub.3); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 133.78 (s, OCH.sub.2CHCH.sub.2), 118.54 (s, OCH.sub.2CHCH.sub.2), 74.11 (d, J=12.7 Hz, OCH.sub.2CHCH.sub.2), 63.81 (d, .sup.2J.sub.CP=167.1 Hz, CH.sub.2P C.sub.1), 62.54 (d, .sup.3J.sub.CP=6.3 Hz, OCH.sub.2CH.sub.3), 16.53 (d, .sup.3J.sub.CP=6.0 Hz, OCH.sub.2CH.sub.3): .sup.31P NMR (CDCl.sub.3) ? (ppm): 21.58.

Step 2: Preparation of Allyloxymethylphosphonic Acid (Phn-1C-Allo) (S3)

[0072] ##STR00014##

[0073] 1.7 ml of bromotrimethylsilane (TMSBr) (12.5 mmol, 2.5 eq.) were added to a solution of PhnEt-1C-Allo (1 eq., 1.1 g, 5 mmol) in 15 ml of dry methylene chloride (DCM). After 20 h stirring at 30? C., the mixture was concentrated under reduced pressure. Methanol (20 ml) was added, and the solution was stirred at room temperature for 5 h. The solvent was evaporated, and the product was dried under vacuum. 0.75 g (99% of th.) of the desired phosphonic acid Phn-1C-Allo were isolated as a colorless liquid.

[0074] RI n.sub.D.sup.20? C.: 1.4773; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 9.78 (s, 2H, 2?OH), 5.97-5.78 (m, 1H, CH.sub.2CH?CH.sub.2), 5.41-5.21 (m, 2H, CH.sub.2CH?CH.sub.2), 4.15 (d, J=5.7 Hz, 2H, CH.sub.2CH?CH.sub.2), 3.85 (d, J=8.8 Hz, 2H, PCH.sub.2O); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 133.19 (s, OCH.sub.2CHCH.sub.2), 119.51 (s, OCH.sub.2CHCH.sub.2), 74.44 (d, J=12.5 Hz, OCH.sub.2CHCH.sub.2), 63.81 (d, .sup.2J.sub.CP=167.9 Hz, CH.sub.2P C.sub.1); .sup.31P NMR (CDCl.sub.3) ? (ppm): 23.73; HR-MS (MeOH, ESI, m/z): calcd. 152.09, found 152.07 [M].

Synthesis Example 4Preparation of 6-allyloxyhexylphosphonic acid (Phn-6C-Allo) (S4)

[0075] Step 1: Preparation of 6-allyloxyhexylphosphonic acid diethylester (PhnEt-6C-Allo)

##STR00015##

[0076] The synthesis was conducted in analogy to Synthesis Example 3, Step 1, from 6-hydroxyhexylphosphonic acid (PhnEt-6COH) (1 eq., 3.1 g, 13 mmol) with allyl bromide (1.5 eq., 1.7 ml, 19.5 mmol) and sodium hydride in paraffin oil (1.9 eq., 0.6 g, 24.7 mmol). By means of column chromatography (EE), 1.4 g (49% of th.) of the desired phosphonate PhnEt-6C-Allo were isolated as a colorless liquid.

[0077] DC (EE/MeOH, 19:1) R.sub.f=0.47; RI n.sub.D.sup.2? C.: 1.4461; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 5.98-5.81 (ddt, .sup.1J.sub.HH=17.3, .sup.2J.sub.HH=10.4, .sup.3J.sub.HH=5.6 Hz, 1H, CH?CH.sub.2), 5.24 (dq, .sup.1J.sub.HH=17.2, .sup.2J.sub.HH=1.7 Hz, 1H, CH?CH.sub.2). 5.15 (dq, .sup.1J.sub.HH=10.4, .sup.2J.sub.HH=1.4 Hz, 1H, CH?CH.sub.2), 4.16-4.00 (m, 4H, 2?OCH.sub.2CH.sub.3), 3.94 (dt, .sup.1J.sub.HH=5.8, .sup.2J.sub.HH=1.4 Hz, 2H, OCH.sub.2CH), 3.40 (1, .sup.2J.sub.HH=6.6 Hz, 2H, CH.sub.2OCH.sub.2CH), 1.77-1.48 (m, 6H, CH.sub.2P C.sub.1, CH.sub.2CH.sub.2O C.sub.5. CH.sub.2C.sub.4), 1.42-1.20 (m, 10H, 2?OCH.sub.2CH.sub.3, CH.sub.2C.sub.3, CH.sub.2CH.sub.2P); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 135.17 (s, CH.sub.2CH?CH.sub.2), 116.83 (s, CH.sub.2CH?CH.sub.2), 71.92 (s, CH.sub.2CH?CH.sub.2), 70.37 (s, CH.sub.2O), 61.49 (d, .sup.2J.sub.CP=6.6 Hz, OCH.sub.2CH.sub.3), 30.55 (d, .sup.3J.sub.CP=16.8 Hz, CH.sub.2CH.sub.2CH.sub.2P), 29.63 (s, CH.sub.2CH.sub.2O C.sub.5), 25.84 (s, .sup.4J.sub.CP=1.3 Hz, CH.sub.2C.sub.4), 25.76 (d, .sup.1J.sub.CP=140.6 Hz, CH.sub.2P C.sub.1), 22.50 (d, .sup.2J.sub.CP=5.1 Hz, PCH.sub.2CH.sub.2), 16.62 (d, .sup.3J.sub.CP=6.0 Hz, OCH.sub.2CH.sub.3); .sup.31P NMR (CDCl.sub.3) ? (ppm): 32.55.

Step 2: Preparation of 6-allyloxyhexylphosphonic acid (Phn-6C-Allo) (S4)

[0078] ##STR00016##

[0079] The synthesis was conducted in analogy to Synthesis Example 3, Step 2, from PhnEt-6C-Allo (1 eq., 1.4 g, 5 mmol) with TMSBr (2.5 eq., 1.7 ml, 12.5 mmol) to isolate 0.95 g (99% d. Th.) of the desired phosphonic acid Phn-6C-Allo as a brown viscous liquid. RI n.sub.D.sup.2? C.: 1.4775; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 9.03-8.47 (m, 2H, 2?OH), 5.91 (ddt, .sup.1J.sub.HH=17.2, .sup.2J.sub.HH=10.3, .sup.3J.sub.HH=5.7 Hz, 1H, CH?CH.sub.2), 5.27 (dq, .sup.1J.sub.HH=17.2, .sup.2J.sub.HH=1.6 Hz, 1H, CH?CH.sub.2), 5.18 (dq, .sup.1J.sub.HH=10.4, .sup.2J.sub.HH=1.4 Hz, 1H, CH?CH.sub.2), 3.98 (dt, .sup.1J.sub.HH=5.7, .sup.2J.sub.HH=1.4 Hz, 2H, OCH.sub.2CH), 3.45 (t, .sup.3J.sub.HH=6.6 Hz, 2H, CH.sub.2OCH.sub.2CH), 1.88-1.73 (m, 2H, PCH.sub.2), 1.62 (m, 4H, CH.sub.2CH.sub.2O C.sub.5, CH.sub.2C.sub.4), 1.40 (m, 4H, PCH.sub.2CH.sub.2C.sub.2, PCH.sub.2CH.sub.2CH.sub.2C.sub.3); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 134.70 (s, CH.sub.2CH?CH.sub.2), 117.38 (s, CH.sub.2CH?CH.sub.2), 71.97 (s, CH.sub.2CH?CH.sub.2), 70.43 (s, CH.sub.2O), 30.15 (d, .sup.3J.sub.CP=16.9 Hz, CH.sub.2CH.sub.2CH.sub.2P), 29.35 (s, CH.sub.2CH.sub.2O C.sub.5), 25.65 (s, CH.sub.2C.sub.4), 25.53 (d, .sup.1J.sub.CP=141 Hz, CH.sub.2P C.sub.1), 21.96 (d, .sup.2J.sub.CP=5.1 Hz, PCH.sub.2CH.sub.2C.sub.2); .sup.31P NMR (CDCl.sub.3) ? (ppm): 36.26; HR-MS (MeOH, ESI, m/z): calcd. 222.22, found 222.20 [M].

Synthesis Example 5Preparation of 6-(2,3-bis(allyloxy)propylthio)hexylphosphonic acid (Phn-6C-bisAllo) (S5)

Step 1: Preparation of 6-(2,3-bis(allyloxy)propylthio)hexylphosphonic acid diethylester (PhnEt-6C-bisAllo)

[0080] ##STR00017##

[0081] The synthesis was conducted in analogy to Synthesis Example 3, Step 1, from 6-(2,3-dihydroxypropylthio)hexylphosphonic acid diethylester (PhnEt-6C-thioglyc) (1 eq., 3.1 g, 13 mmol) with allyl bromide (1.5 eq., 1.7 ml, 19.5 mmol) and sodium hydride in paraffin oil (1.9 eq., 0.6 g, 24.7 mmol). By means of column chromatography (EE), 1.4 g (49% of th.) of the desired phosphonate PhnEt-6C-bisAllo were isolated as a colorless liquid.

[0082] DC (EE) R.sub.f=0.3; RI n.sub.D.sup.2? C.: 1.4775; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 5.99-5.82 (m, 2H, CH?CH.sub.2). 5.32-5.09 (m, 4H, CH?CH.sub.2), 4.23-3.95 (m, 8H, OCH.sub.2CH.sub.3, OCH.sub.2), 3.74-3.49 (m, 3H, CHO, CH.sub.2O), 2.80-2.61 (m, 2H, alkyl-CH.sub.2SCH.sub.2), 2.59-2.47 (m, 2H, alkyl-CH.sub.2SCH.sub.2), 1.79-1.50 (m, 6H, PCH.sub.2, PCH.sub.2CH.sub.2, CH.sub.2CH.sub.2CH.sub.2S), 1.38 (m, 4H, PCH.sub.2CH.sub.2CH.sub.2, CH.sub.2CH.sub.2S), 1.31 (t, .sup.3J.sub.HH=7.0 Hz, 6H, OCH.sub.2CH.sub.3); .sup.13C-NMR (101 MHz, CDCl.sub.3) ? (ppm): 134.93 (s, 2?CH?CH.sub.2), 117.00 (s, 2?CH?CH.sub.2), 78.2 (s, CHO), 72.35 (s, CH.sub.2O), 71.18 (d, .sup.3J.sub.CP==3.6 Hz, 2?OCH.sub.2CH?CH.sub.2), 61.42 (d, .sup.3J.sub.CP=6.5 Hz, OCH.sub.2CH.sub.3), 33.61 (s, CH.sub.2SCH.sub.2), 33.05 (s, alkyl-CH.sub.2SCH.sub.2), 30.22 (d, .sup.3J.sub.CP=16.8 Hz, PCH.sub.2CH.sub.2CH.sub.2), 29.44 (s, CH.sub.2CH.sub.2CH.sub.2S), 28.33 (s, CH.sub.2CH.sub.2S), 25.67 (d, .sup.1J.sub.CP=140.6 Hz, PCH.sub.2), 22.36 (d, .sup.2J.sub.CP=5.2 Hz, PCH.sub.2CH.sub.2), 16.45 (d, .sup.3J.sub.CP=6.0 Hz, OCH.sub.2CH.sub.3); .sup.31P NMR (CDCl.sub.3) ? (ppm): 32.40.

Step 2: Preparation of 6-(2,3-bis(allyloxy)propylthio)hexylphosphonic acid (Phn-6C-bisAllo) (S5)

[0083] ##STR00018##

[0084] The synthesis was conducted in analogy to Synthesis Example 3, Step 1, from PhnEt-6C-bisAllo (1 eq., 0.8 g, 1.9 mmol) with TMSBr (2.5 eq., 0.6 ml, 4.75 mmol) to isolate 0.5 g (75% of th.) of the desired phosphonic acid Phn-6C-bisAllo as a brown viscous liquid.

[0085] RI n.sub.D.sup.20? C.: 1.5084; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.02-5.80 (m, 2H, CH?CH.sub.2), 5.32-5.14 (m, 4H, CH?CH.sub.2), 4.19-3.98 (m, 4H, OCH.sub.2), 3.75-3.52 (m, 3H, CHO, CH.sub.2 O), 2.77-2.62 (m, 2H, alkyl-CH.sub.2SCH.sub.2), 2.60-2.50 (m, 2H, alkyl-CH.sub.2SCH.sub.2), 1.87-1.70 (m, 2H, PCH.sub.2), 1.70-1.49 (m, 4H, PCH.sub.2CH.sub.2; CH.sub.2CH.sub.2CH.sub.2S), 1.45-1.33 (m, 4H, PCH.sub.2CH.sub.2CH.sub.2, CH.sub.2CH.sub.2S); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 135.12 (s, CH?CH.sub.2), 134.74 (s, CH?CH.sub.2), 117.20 (s, 2?CH?CH.sub.2), 78.10 (s, CHO), 72.51 (s, CH.sub.2O), 71.30 (d, .sup.3J.sub.CP=3.7 Hz, 2?OCH.sub.2CH?CH.sub.2), 33.67 (s, CH.sub.2SCH.sub.2), 33.13 (s, alkyl-CH.sub.2SCH.sub.2), 30.22 (d, .sup.3J.sub.CP=17.1 Hz, PCH.sub.2CH.sub.2CH.sub.2), 29.45 (s, CH.sub.2CH.sub.2CH.sub.2S), 28.27 (s, CH.sub.2CH.sub.2S), 25.32 (d, .sup.1J.sub.CP=141 Hz, PCH.sub.2), 21.95 (d, .sup.2J.sub.CP=5.5 Hz, PCH.sub.2CH.sub.2); .sup.31P NMR (CDCl.sub.3) ? (ppm): 37.32; HR-MS (MeOH, ESI, m/z): calcd. 352.43, found 352.47 [M].

Synthesis Example 6Preparation of Allyloxycarbonyloxymethylphosphonic Acid (Phn-1C-Allcarb) (S6)

Step 1: Preparation of Allyloxycarbonyloxymethylphosphonic Acid Diethylester (PhnEt-1C-Allcarb)

[0086] ##STR00019##

[0087] A three-necked flask was charged with hydroxymethylphosphonic acid diethylester (PhnEt-1COH) (1 eq., 2.2 ml, 15 mmol) and pyridine (4 eq., 4.8 ml, 60 mmol) in 50 ml of DCM under argon. Chloroformic acid allyl ester (1.3 eq., 2.1 ml, 19.5 mmol) was added dropwise at 0? C. via a septum. After 1 h of stirring at 0? C., the ice bath was removed, and the reaction was stirred at room temperature overnight. The raw product was dissolved in EE, and the precipitate (pyridinium salts) was collected by filtration. After evaporating the solvent, 2.9 g (77% of th.) of the desired phosphonate PhnEt-1C-Allcarb were isolated as a colorless liquid.

[0088] DC (EE) R.sub.f=0.5; RI n.sub.f.sup.20? C.: 1.4460; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.00-5.85 (m, 1H, CH.sub.2CH?CH.sub.2). 5.43-5.22 (m, 2H, CH.sub.2CH?CH.sub.2), 4.69-4.61 (m, 2H, CH.sub.2CH?CH.sub.2), 4.43 (d, .sup.3J.sub.HH=8.5 Hz, 2H, PCH.sub.2O), 4.25-4.10 (m, 4H, OCH.sub.2CH.sub.3), 1.35 (t, .sup.3J.sub.HH=7.0 Hz, 6H, OCH.sub.2CH.sub.3); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 154.71 (d, .sup.3J.sub.CP=9.5 Hz, OC?OO), 131.26 (s, OCH.sub.2CHCH.sub.2), 119.42 (s, OCH.sub.2CHCH.sub.2), 69.31 (s, OCH.sub.2CHCH.sub.2), 63.07 (d, .sup.2J.sub.CP=6.5 Hz, OCH.sub.2CH.sub.3), 60.32 (d, .sup.1J.sub.CP=168.5 Hz, CH.sub.2P C.sub.1), 16.49 (d, .sup.3J.sub.CP=6.0 Hz, OCH.sub.2CH.sub.3); .sup.31P NMR (CDCB) ? (ppm): 17.74.

Step 2: Preparation of Allyloxycarbonyloxymethylphosphonic Acid (Phn-1C-Allcarb) (S6)

[0089] ##STR00020##

[0090] The synthesis was conducted in analogy to Synthesis Example 3, Step 2, from PhnEt-1C-Allcarb (1 eq., 2.5 g, 10 mmol) with TMSBr (2.5 eq., 3.3 ml, 25 mmol) to isolate 1.76 g (99% of th.) of the desired phosphonic acid Phn-1C-Allcarb as a colorless liquid. RI n.sub.D.sup.2? C.: 1.4566; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 9.52 (s, 2H, OH), 6.00-5.81 (m, 1H, CH.sub.2CH?CH.sub.2), 5.43-5.22 (m, 2H, CH.sub.2CH?CH.sub.2), 4.65 (d, .sup.3J.sub.HH=5.7 Hz, 2H, CH.sub.2CH?CH.sub.2), 4.46 (d, .sup.3J.sub.HH=8.8 Hz, 2H, PCH.sub.2O); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 154.87 (d, .sup.3J.sub.CP=9.5 Hz, OC?OO), 131.19 (s, OCH.sub.2CHCH.sub.2), 119.58 (s, OCH.sub.2CHCH.sub.2), 69.64 (s, OCH.sub.2CHCH.sub.2), 61.19 (d, J.sub.CP=169.5 Hz, CH.sub.2P C.sub.1); .sup.31P NMR (CDCl.sub.3) ? (ppm): 19.11; HR-MS (MeOH, ESI, m/z): calcd. 196.09, found 196.06 [M].

Synthesis Example 7Preparation of 6-(allyloxycarbonyloxy)hexylphosphonic acid (Phn-6C-Allcarb) (S7)

Step 1: Preparation of 6-(allyloxycarbonyloxy)hexylphosphonic acid diethylester (PhnEt-6C-Allcarb)

[0091] ##STR00021##

[0092] The synthesis was conducted in analogy to Synthesis Example 6, Step 1, from 6-hydroxyhexylphosphonic acid diethylester (PhnEt-6COH) (1 eq., 2.4 g, 10 mmol) with chloroformic acid allyl ester (1.5 eq., 1.6 ml, 15 mmol) and pyridine (4 eq., 3.2 ml, 40 mmol), wherein after evaporation of the solvent, 2.2 g (68% of th.) of the desired phosphonate PhnEt-6C-Allcarb were isolated as a yellowish viscous liquid.

[0093] DC (EE/MeOH, 9:1) R.sub.f=0.51; RI n.sub.d.sup.20? C.: 1.4463; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 5.98-5.82 (m, 1H, CH.sub.2CH?CH.sub.2), 5.39-5.20 (m, 2H, CH.sub.2CH?CH.sub.2), 4.64-4.53 (m, 2H, CH.sub.2CH?CH.sub.2), 4.15-3.94 (m, 6H, CH.sub.2O C.sub.6, OCH.sub.2CH.sub.3), 1.83-1.47 (m, 4H, CH.sub.2P C.sub.1, CH.sub.2CH.sub.2O C.sub.5), 1.44-1.19 (m, 12H, CH.sub.2 C.sub.2-C.sub.4, OCH.sub.2CH.sub.3); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 155.15 (s, OC?OO), 131.67 (s, OCH.sub.2CHCH.sub.2), 118.93 (s, OCH.sub.2CHCH.sub.2), 68.41 (s, CH.sub.2CH.sub.2O C.sub.6), 68.05 (s, OCH.sub.2CHCH.sub.2), 61.49 (d, .sup.2J.sub.CP=6.4 Hz, OCH.sub.2CH.sub.3), 32.54 (s, CH.sub.2CHO C.sub.5), 30.21 (d, .sup.3J.sub.CP=16.8 Hz, CH.sub.2CH.sub.2CH.sub.2P C.sub.3), 25.68 (d, J.sub.CP=140.7 Hz, CH.sub.2P C.sub.1), 25.32 (d, .sup.4J.sub.CP=1.2 Hz, CH.sub.2 C.sub.4), 22.40 (d, .sup.2J.sub.CP=5.1 Hz, CH.sub.2CH.sub.2P C.sub.2), 16.55 (d, .sup.3J.sub.CP=6.0 Hz, OCH.sub.2CH.sub.3); .sup.31P NMR (CDCl.sub.3) ? (ppm): 32.23.

Step 2: Preparation of 6-(allyloxycarbonyloxy)hexylphosphonic acid (Phn-6C-Allcarb) (S7)

[0094] ##STR00022##

[0095] The synthesis was conducted in analogy to Synthesis Example 3, Step 2, from PhnEt-6C-Allcarb (1 eq., 2.1 g, 6.5 mmol) with TMSBr (2.5 eq., 2.2 ml, 16.25 mmol) to isolate 1.5 g (87% of th.) of the desired phosphonic acid Phn-6C-Allcarb as a brown viscous liquid.

[0096] .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.02-5.84 (m, 1H, CH.sub.2CH?CH.sub.2), 5.40-5.21 (m, 2H, CH.sub.2CH?CH.sub.2), 4.67-4.53 (m, 2H, CH.sub.2CH?CH.sub.2), 4.13 (t, J=6.6 Hz, 2H, CH.sub.2O), 1.94-1.56 (m, 6H, CH.sub.2P C.sub.1, CH.sub.2CH.sub.2O C.sub.5, CH.sub.2 C.sub.4), 1.49-1.35 (m, 4H, CH.sub.2CH.sub.2P C.sub.2, CH.sub.2 C.sub.3): 13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 155.13 (s, OC?OO), 131.61 (s, OCH.sub.2CHCH.sub.2), 118.92 (s, OCH.sub.2CHCH.sub.2), 68.40 (s, CH.sub.2O C.sub.6), 68.01 (s, OCH.sub.2CHCH.sub.2), 30.02 (d, .sup.3J.sub.CP=17.0 Hz, CH.sub.2CH.sub.2CH.sub.2P C.sub.3), 28.52 (s, CH.sub.2CH.sub.2O C.sub.5), 25.45 (d, .sup.1J.sub.CP=141 Hz, CH.sub.2P C.sub.1), 25.31 (s, CH.sub.2 Cc), 21.93 (d, .sup.2J.sub.CP=5.0 Hz, PCH.sub.2CH.sub.2 C.sub.2); .sup.31P NMR (CDCl.sub.3) ? (ppm): 36.31; HR-MS (MeOH, ESI, m/z): calcd. 238.26, found 238.31 [M].

Synthesis Example 8Preparation of 6-(2,3-bis(allyloxycarbonyloxy)propylthio)hexylphosphonic acid (Phn-6C-bisAllcarb) (S8)

Step 1: Preparation of 6-(2,3-bis(allyloxycarbonyloxy)propylthio)hexylphosphonic acid diethylester (PhnEt-6C-bisAllcarb)

[0097] ##STR00023##

[0098] The synthesis was conducted in analogy to Synthesis Example 6, Step 1, from 6-(2,3-dihydroxypropylthio)hexylphosphonic acid diethylester (PhnEt-6C-thioglyc) (1 eq., 3.3 g, 10 mmol) with allyl chloroformic acid ester (4 eq., 4.3 ml, 40 mmol) and pyridine (9 eq., 7.3 ml, 90 mmol). By means of column chromatography (EE), 3.38 g (68% of th.) of the desired phosphonate PhnEt-6C-bisAllcarb were isolated as a brown viscous liquid.

[0099] DC (EE) R.sub.f=0.4; RI n.sub.D.sup.2? C.: 1.4774; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.00-5.85 (m, 2H, 2H, 2?CH.sub.2CH?CH.sub.2), 5.41-5.22 (m, 4H, 2?CH.sub.2CH?CH.sub.2), 5.01-4.92 (m, 1H, CHO), 4.67-4.58 (m, 4H, CH.sub.2CH?CH.sub.2), 4.48 (dd, J=11.9, 3.2 Hz, 1H, CH.sub.2OC?O), 4.30 (dd, J=11.9, 5.9 Hz, 1H, CH.sub.2OC?O), 4.18-3.97 (m, 4H, OCH.sub.2CH.sub.3), 2.83-2.69 (m, 2H, SCH.sub.2CH), 2.60-2.52 (m, 2H, CH.sub.2CH.sub.2S C.sub.6), 1.79-1.51 (m, 6H, PCH.sub.2 C.sub.1, PCH.sub.2CH.sub.2 C.sub.2, CH.sub.2CH.sub.2S C.sub.5), 1.38 (m, 4H, CH.sub.2 C.sub.3-C.sub.4), 1.31 (t, J=7.1 Hz, 6H, OCH.sub.2CH.sub.3); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 154.77 (s, OC?OO), 154.42 (s, OC?OO), 131.44 (s, OCH.sub.2CHCH.sub.2), 119.29 (s, OCH.sub.2CHCH.sub.2), 119.21 (s, OCH.sub.2CHCH.sub.2), 74.84 (s, CHO), 68.90 (d, J=3.1 Hz, 2?OCH?CHCH.sub.2), 66.97 (s, CH.sub.2O), 61.53 (d, .sup.2J.sub.CP=6.5 Hz, OCH.sub.2CHs), 32.80 (s, SCH.sub.2CH), 31.95 (s, CH.sub.2CH.sub.2S), 30.27 (d, .sup.3J.sub.CP=16.7 Hz, CH.sub.2CH.sub.2CH.sub.2P C.sub.3), 29.33 (s, CH.sub.2CH.sub.2S), 28.34 (d, .sup.4J.sub.CP=1.3 Hz, CH.sub.2 C.sub.4), 25.77 (d, .sup.1J.sub.CP=140.6 Hz, PCH.sub.2 C.sub.1), 22.47 (d, .sup.2J.sub.CP=5.2 Hz, PCH.sub.2CH.sub.2 C.sub.2), 16.61 (d, .sup.3J.sub.CP=6.1 Hz, OCH.sub.2CH.sub.3); .sup.31P NMR (CDCl.sub.3) 0 (ppm): 32.33.

Step 2: Preparation of 6-(2,3-bis(allyloxycarbonyloxy)propylthio)hexylphosphonic acid (Phn-6C-bisAllcarb) (S8)

[0100] ##STR00024##

[0101] The synthesis was conducted in analogy to Synthesis Example 3, Step 2, from PhnEt-6C-bisAllcarb (1 eq., 1.9 g, 3.8 mmol) with TMSBr (2.5 eq., 1.3 ml, 9.5 mmol) to isolate 1.61 g (87% of th.) of the desired phosphonic acid Phn-6C-bisAllcarb as a brown viscous liquid.

[0102] RI n.sub.D.sup.2? C.: 1.4877; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 7.90 (s, 2H, 2?CH.sub.2CH?CH.sub.2), 6.01-5.84 (m, 2H), 5.43-5.23 (m, 4H, 2?CH.sub.2CH?CH.sub.2), 5.04-4.92 (m, 1H, CHO), 4.68-4.58 (m, 4H, 2?CH.sub.2CH?CH.sub.2), 4.48 (dd, J.sub.HH=11.9, 3.1 Hz, 1H, CH.sub.2OC?O), 4.31 (dd, J.sub.HH=11.9, 6.0 Hz, 1H, CH.sub.2OC?O), 2.80-2.72 (m, 2H, SCH.sub.2CH), 2.62-2.52 (m, 2H, CH.sub.2CH.sub.2S C.sub.8), 1.90-1.73 (m, 2H, PCH.sub.2 C.sub.1), 1.70-1.53 (m, 4H, PCH.sub.2CH.sub.2 C.sub.2, CH.sub.2CH.sub.2S C.sub.5), 1.47-1.35 (m, 4H, CH.sub.2 C.sub.3-C.sub.4); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 154.81 (s, OC?OO), 154.49 (s, OC?OO), 131.44 (s, OCH.sub.2CHCH.sub.2), 119.29 (s, OCH.sub.2CHCH.sub.2), 119.21 (s, OCH.sub.2CHCH.sub.2), 74.84 (s, CHO), 68.97 (d, J=3.1 Hz, 2?OCH.sub.2CHCH.sub.2), 67.03 (s, CH.sub.2O), 32.72 (s, SCH.sub.2CH), 31.94 (s, CH.sub.2CH.sub.2S), 29.90 27 (d, 3J.sub.CP=17.1 Hz, CH.sub.2CH.sub.2CH.sub.2P C.sub.3), 29.21 (s, CH.sub.2CH.sub.2S), 28.15 (d, .sup.4J.sub.CP=1.3 Hz, CH.sub.2 C.sub.4), 25.32 (d, .sup.1J.sub.CP=140.4 Hz, PCH.sub.2 C.sub.1), 21.88 (d, .sup.2J.sub.CP=5.1 Hz, PCH.sub.2CH.sub.2 C.sub.2); .sup.31P NMR (CDCB) ? (ppm): 37.05; HR-MS (MeOH, ESI, m/z): calcd. 440.44, found 440.41 [M].

Synthesis Examples 9 and 10Preparation of Comparative Primers with Vinyl (enyl) as PG and Phosphonic Acid (Phn) as AM

Synthesis Example 9Preparation of hex-5-en-1-yl phosphonic acid (Phn-6C-Enyl) (S9)

Step 1: Preparation of hex-5-en-1-yl phosphonic acid diethylester (PhnEt-6C-Enyl)

[0103] ##STR00025##

[0104] A distillation apparatus provided with a Vigreux column was charged with 9.8 g (1 eq., 60 mmol) of hex-5-en-1-ylbromide, 12.0 g (1.2 eq., 72 mmol) of triethyl phosphite, and 11 mg of p-methoxyphenol (hydroquinone monomethyl ether, MEHQ) under argon atmosphere. The solution was heated to 140? ? C. for 24 h, forming ethyl bromide (b.p. 38? C.) as a byproduct, which was distilled off during the reaction. The reaction progress was monitored by .sup.31P NMR. After the reaction was complete, the product was fractionally distilled off under high vacuum (0.011 mbar) at 75? C. to obtain 8.99 g (68% of th.) of the desired phosphonate PhnEt-6C-Enyl as a colorless liquid.

[0105] DC (PE/EE 1:2) R.sub.f=0.23; RI n.sub.D.sup.2? C.: 1.4540; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 5.84-5.69 (m, 1H, CH?CH.sub.2), 5.04-4.89 (m, 2H, CH?CH.sub.2), 4.16-4.00 (m, 4H, OCH.sub.2CH.sub.3), 2.11-2.00 (m, 2H, CH.sub.2CH), 1.78-1.53 (m, 4H, CH.sub.2), 1.51-1.41 (m, 2H, PCH.sub.2), 1.30 (1, .sup.3J.sub.HH=7.1 Hz, 6H, OCH.sub.2CH.sub.3); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 138.31 (s, CH?CH.sub.2), 114.92 (s, CH?CH.sub.2), 61.50 (d, J=6.5 Hz, OCH.sub.2CH.sub.3), 33.31 (d, .sup.4J.sub.CP=1.4 Hz, CH.sub.2CH), 29.88 (d, .sup.3J.sub.CP=17.0 Hz, PCH.sub.2CH.sub.2CH.sub.2), 26.72-24.62 (d, .sup.1J.sub.CP=140.6 Hz, PCH.sub.2, 22.03 (d, .sup.2J.sub.CP=5.2 Hz, PCH.sub.2CH.sub.2), 16.62 (d, .sup.3J.sub.CP=6.1 Hz, OCH.sub.2CH.sub.3); .sup.31P NMR (CDCl.sub.3) ? (ppm): 32.31.

Step 2: Preparation of hex-5-en-1-yl phosphonic acid (Phn-6C-Enyl) (S9)

[0106] ##STR00026##

[0107] The synthesis was conducted in analogy to Synthesis Example 3, Step 2, from PhnEt-6C-Enyl (1 eq., 3.3 g, 15 mmol) with TMSBr (3 eq., 6 ml, 45 mmol) to isolate 2.51 g (84% of th.) of the desired phosphonic acid Phn-6C-Enyl as a colorless solid.

[0108] Fp.: 97.2-100.1? C.: 1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 9.47 (s, 2H, OH), 5.88-5.67 (m, 1H, CH?CH.sub.2). 5.08-4.89 (m, 2H, CH?CH.sub.2), 2.12-1.99 (m, 2H, CH.sub.2CH), 1.85-1.55 (m, 4H, 2?CH.sub.2), 1.55-1.41 (m, 2H, PCH.sub.2); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 138.17 (s, CH?CH.sub.2), 114.88 (s, CH?CH.sub.2), 33.16 (s, CH.sub.2CH), 29.58 (d, .sup.3J.sub.CP=17.0 Hz, PCH.sub.2CH.sub.2CH.sub.2), 26.15-23.79 (d, .sup.1J.sub.CP=140.8 Hz, PCH.sub.2), 21.49 (d, .sup.2J.sub.CP=5.0 Hz, PCH.sub.2CH.sub.2); .sup.31P NMR (CDCl.sub.3) ? (ppm): 37.41.

Synthesis Example 10Preparation of undec-10-en-1-yl phosphonic acid (Phn-11C-Enyl) (S10)

Step 1: Preparation of undec-10-en-1-yl phosphonic acid diethylester (PhnEt-11C-Enyl)

[0109] ##STR00027##

[0110] The synthesis was conducted in analogy to Synthesis Example 8, Step 1, from undec-10-en-1-ylbromide (1 eq., 8.2 g, 35 mmol), triethyl phosphite (1.3 eq., 8 ml, 45.5 mmol), and 20 mg of MEHQ. After the reaction was complete, the product was purified by column chromatography (EE) to isolate 6.75 g (66% of th.) of the desired phosphonate PhnEt-11C-Enyl as a yellowish viscous liquid.

[0111] DC (EE) R.sub.f=0.38; RI n.sub.D.sup.2? C.: 1.4462; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 5.86-5.71 (m, 1H, CH?CH.sub.2), 5.01-4.93 (m, 1H, CH?CH.sub.2), 4.93-4.87 (m, 1H, CH?CH.sub.2), 4.16-3.99 (m, 4H, OCH.sub.2CH.sub.3), 2.09-1.94 (m, 2H, CH.sub.2CH?CH.sub.2), 1.78-1.64 (m, 2H, PCH.sub.2), 1.63-1.51 (m, 2H, PCH.sub.2CH.sub.2), 1.41-1.20 (m, 18H, 2?OCH.sub.2CH.sub.3, 6?CH.sub.2 C.sub.3-C.sub.8); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 139.40 (s, CH?CH.sub.2), 114.24 (s, CH?CH.sub.2 C.sub.11), 61.49 (d, J=6.4 Hz, OCH.sub.2CH.sub.3), 33.90 (s, CH.sub.2CH), 30.71 (d, .sup.3J.sub.CP=17.0 Hz, PCH.sub.2CH.sub.2CH.sub.2 C.sub.3), 29.51 (s, CH.sub.2 C.sub.6), 29.42 (s, CH.sub.2 C.sub.7), 29.19 (s, CH.sub.2 C.sub.5 C.sub.8)), 29.02 (s, CH.sub.2 C.sub.4), 26.66-24.96 (d, .sup.1J.sub.CP=140.4 Hz, PCH.sub.2 C.sub.1), 22.51 (d, .sup.2J.sub.CP=5.3 Hz, PCH.sub.2CH.sub.2 C.sub.2), 16.60 (d, .sup.3J.sub.CP=6.0 Hz, OCH.sub.2CH.sub.3); .sup.31P NMR (CDCl.sub.3) ? (ppm): 32.65.

Step 2: Preparation of undec-10-en-1-yl phosphonic acid (Phn-11C-Enyl) (S10)

[0112] ##STR00028##

[0113] The synthesis was conducted in analogy to Synthesis Example 3, Step 2, from PhnEt-11C-Enyl (1 eq., 5.8 g, 20 mmol) with TMSBr (3 eq., 8 ml, 60 mmol) to isolate 4.65 g (99% of th.) of the desired phosphonic acid Phn-11C-Enyl as a colorless solid.

[0114] Fp.: 74.2-76.9? C.; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 5.91-5.70 (m, 1H, CH?CH.sub.2), 5.02-4.96 (m, 1H, CH?CH.sub.2), 4.95-4.91 (m, 1H, CH?CH.sub.2), 2.12-1.95 (m, 2H, CH.sub.2CH?CH.sub.2), 1.81-1.69 (m, 2H, PCH.sub.2), 1.67-1.55 (m, 2H, PCH.sub.2CH.sub.2), 1.46-1.13 (m, 12H, 6?CH.sub.2 C.sub.3-C.sub.6); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 139.24 (s, CH?CH.sub.2), 114.28 (s, CH?CH.sub.2 C.sub.11), 33.95 (s, CH.sub.2CH), 30.56 (d, .sup.3J.sub.CP=17.1 Hz, PCH.sub.2CH.sub.2CH.sub.2 C.sub.3), 29.56 (s, CH.sub.2 C.sub.6), 29.46 (s, CH.sub.2 C.sub.7), 29.24 (s, CH.sub.2 C.sub.8), 29.17 (s, CH.sub.2 C.sub.5), 29.07 (s, CH.sub.2 C.sub.4), 25.34 (d, .sup.1J.sub.CP=141 Hz, PCH.sub.2 C.sub.1), 22.12 (d, .sup.2J.sub.CP=5.0 Hz, PCH.sub.2CH.sub.2 C.sub.2); .sup.31P NMR (CDCl.sub.3) ? (ppm): 37.52.

Synthesis Example 11Preparation of a Comparative Primer with Vinyl (Enyl) as PG and 4-pyrocatechyl (Catechol) as AM

4-Allylpyrocatechol (Catechol-3C-Enyl) (S11)

[0115] ##STR00029##

[0116] The synthesis known from literature was carried out as described in Donovan et al., RSC Adv. 4, 61927-61935 (2014) from 4-allyl-2-methoxyphenol (Eugenol, Eug) by silylation with triethylsilane (TES) with the cleavage of CH.sub.4 in the presence of tris(pentafluorophenyl)borane (TPFPB), followed by hydrolysis of the double-silylated intermediate Eug-TES with 1 M of aqueous HCl to obtain the deisired Catechol-3C-Enyl.

[0117] DC (PE:EE 4:1) R.sub.f=0.43; Fp.: 45.1-45.3? C.: .sup.1H NMR (400 MHZ, MeOD-d) ? (ppm): 6.89-6.53 (m, 3H, ArH), 6.03-5.80 (m, 1H, CH?CH.sub.2), 5.13-5.06 (m, 1H, CH?CH.sub.2), 5.02 (1, .sup.2J.sub.HH=1.5 Hz, 1H, CH?CH.sub.2). 3.28 (d, .sup.3J.sub.HH=6.7 Hz, 2H, CH.sub.2CH?CH.sub.2); .sup.13C-NMR (101 MHZ, MeOD-d) ? (ppm): 143.39 (s, ArC.sub.qO), 141.66 (s, ArC.sub.qO), 137.61 (s, CH?CH.sub.2), 133.31 (s, ArC.sub.q), 121.05 (s, ArC), 115.72 (s, ArC), 115.62 (s, CH?CH.sub.2), 115.36 (s, ArC), 39.51 (s, CH.sub.2CH?CH.sub.2).

Examples 1 to 9Preparation of Primers with Norbornenyl (Norb) as PG and Phosphonic Acid (Phn) or 4-Pyrocatechyl (Catechol) as AM

Example 1Preparation of N-(4-hydroxy-4,4-diphosphonobutyl)-5-norbornene-2-carboxylic acid amide (N-(4-hydroxy-4,4-diphosphonobutyl)alendronic acid amide) (Alendronate-Norb) (E1)

Step 1: Preparation of 5-norbornene-2-carboxylic acid-2,5-dioxopyrrolidine amide (Norb-NHS)

[0118] ##STR00030##

[0119] The synthesis known from literature was carried out as described in Werther et al., Chem. Eur. J. 23(72), 18216-18224 (2017) from 5-norbornene-2-carboxylic acid and 1-hydroxypyrrolidine-2,5-dione in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC.Math.HCl) and 4-dimethylaminopyridine (DMAP) in dry DCM.

[0120] DC (EE/PE, 3:1) R.sub.f=0.74; Fp.: 87.2-94.0? C.; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.21 (dd, .sup.3J.sub.HH=3.0 Hz, .sup.2J.sub.HH=5.3 Hz, 1H, CH?CH), 6.12 (dd, .sup.3J.sub.HH=3.0 Hz, .sup.2J.sub.HH=5.3 Hz, 1H, CH?CH), 3.43-3.35 (m, 1H, CH norb), 3.29-3.19 (m, 1H, CH norb), 2.98 (m, 1H, CHC?O), 2.81 (s, 4H, 2?CH.sub.2), 2.09-1.95 (m, 1H, CH.sub.2 norb), 1.57-1.40 (m, 3H, CH.sub.2 bridge+CH.sub.2 norb), 1.37-1.29 (m, 1H, CH.sub.2 bridge); .sup.13C-NMR (101 MHz, CDCl.sub.3) ? (ppm): 171.75 (s, C?O), 170.08 (s, NC?O), 169.43 (s, NC?O), 138.24 (s, CH?CH), 135.38 (s, CH?CH), 49.76 (s, CH.sub.2 bridge endo), 47.24 (s, CH norb exo), 46.52 (s, CH norb endo), 46.50 (s, CH.sub.2 bridge exo), 42.63 (s, CH norb endo), 41.89 (s, CH norb exo), 40.72 (s, CHC?O endo), 40.40 (s, CHC?O exo), 31.08 (s, CH.sub.2 norb exo) 29.68 (s, CH.sub.2 norb endo), 25.72 (s, 2?CH.sub.2).

Step 2: Preparation of N-(4-hydroxy-4,4-diphosphonobutyl)-5-norbornene-2-carboxylic acid amide sodium salt (Alendronate-Norb) (E1)

[0121] ##STR00031##

[0122] Alendronic acid monosodium salt trihydrate (1 eq., 2.6 g, 8 mmol) was dissolved in 60 ml of deionized water and the pH was adjusted to 8.5 with 1 M of NaOH solution. Norb-NHS (2 eq., 3.8 g, 16 mmol) was dissolved in a second flask in 60 ml of acetonitrile, and the organic solution was added portionwise to the aqueous alendronic acid solution, wherein the pH value was measured after each portion and readjusted to 8.5 when required. After 24 h of stirring at room temperature, the solvents were evaporated, and the raw product was recrystallized from ethanol to isolate 3.5 g (99% of th.) of the desired compound Alendronate-Norb as a colorless solid.

[0123] Fp.: 212.3? C. (dec.); .sup.1H NMR (400 MHz, D.sub.2O) ? (ppm): 6.30-5.93 (m, 2H, CH?CH), 3.21 (t, .sup.3J.sub.HH=6.9 Hz, 1H, CH norb), 3.18-3.13 (m, 2H, CH.sub.2NH), 3.03-2.96 (m, 1H, CH norb), 2.95-2.90 (m, 1H, C.sub.qOH), 2.67 (s, 3H, 3?POH), 2.49-2.35 (m, 1H, CHC?O), 1.99-1.87 (m, 3H, C.sub.qCH.sub.2, CH.sub.2 norb), 1.84-1.71 (m, 2H, CH.sub.2 norb, CH.sub.2 bridge), 1.41-1.35 (m, 1H, CH.sub.2 bridge), 1.35-1.30 (m, 2H, CH.sub.2CH.sub.2NH); .sup.13C-NMR (101 MHZ, D.sub.2O) ? (ppm): 178.77 (s, C?O), 138.32 (s, CH?CH), 132.08 (s, CH?CH), 73.88 (t, .sup.1J.sub.CP=132.2 Hz, C.sub.q), 49.50 (s, CH.sub.2 bridge endo), 46.43 (m, CH norb endo/exo), 45.97 (s, CH.sub.2 bridge exo), 44.12 (s, CH norb endo), 43.97 (s, CH norb exo), 42.56 (s, CHC?O endo), 41.30 (s, CHC?O exo), 40.04 (s, CqCH.sub.2CH.sub.2CH.sub.2NH), 31.19 (s, CqCH.sub.2CH.sub.2CH.sub.2NH), 29.12 (s, CH.sub.2 norb exo), 28.75 (s, CH.sub.2 norb endo), 23.60 (t, .sup.3J.sub.CP=6.4 Hz, CqCH.sub.2CH.sub.2CH.sub.2NH); .sup.31P NMR (D.sub.2O) ? (ppm): 18.31; elementary analysis: calcd. for C.sub.12H.sub.20NNaO.sub.8P.sub.2: C-36.84, H-5.15, N-3.58, Na-5.88, O-32.72, P-15.83; found: C-36.85, H-4.86, N-3.62, Na-5.01, O-33.32, P-15.79.

Example 2Preparation of N-[2-(3,4-dihydroxyphenyl)ethyl]-5-norbornene-2-carboxylic acid amide (Catechol-2C-Norb) (E2)

[0124] ##STR00032##

[0125] The synthesis was conducted in analogy to Synthesis Example 12, Step 2, from Norb-NHS (1.5 eq., 2.3 g, 10 mmol) and dopamine hydrochloride (1 eq., 2.4 g, 15 mmol) in a water/acetonitrile mixture at pH 8.5. The raw product obtained by evaporating the solvent was purified by column chromatography (ethyl acetate:petroleum ether, EE:PE, 1:1-3:1) to obtain 1.4 g (60% of th.) of the desired compound Catechol-2C-Norb as a colorless viscous liquid.

[0126] DC (EE:PE, 3:1) R.sub.f=0.42: .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.82 (d, .sup.3J.sub.HH=8.0 Hz, 1H, CH Ar), 6.73 (d, .sup.3J.sub.HH=2.0 Hz, 1H, CH Ar), 6.54 (dd. .sup.3J.sub.HH=8.1 Hz, 4J.sub.HH=2.0 Hz, 1H, CH Ar), 6.17 (dd, .sup.3J.sub.HH=5.7, .sup.4J.sub.HH=3.1 Hz, 1H, CH?CH), 5.82 (dd, .sup.3J.sub.HH=5.7, .sup.4J.sub.HH==2.8 Hz, 1H, CH?CH), 5.63 (1, .sup.3J.sub.HNCH=5.8 Hz, 1H, NH), 3.42 (q, .sup.3J.sub.HH=6.7 Hz, 2H, CH.sub.2NH), 3.06 (s, 1H, CH norb), 2.95-2.76 (m, 2H, CH norb, CHC?O norb), 2.64 (t, .sup.3J.sub.HH=7.0 Hz, 2H, C.sub.ArCH.sub.2), 2.03-1.82 (m, 1H, CH norb), 1.50-1.34 (m, 1H, CH.sub.2 bridge), 1.34-1.09 (m, 1H, CH.sub.2 bridge); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 176.47 (s, C?O), 145.04 (s, COH), 143.39 (s, COH), 138.31 (s, CH?CH), 132.26 (s, CH?CH), 129.83 (s, C.sub.ArCH.sub.2), 120.50 (s, CH Ar), 115.70 (s, CH Ar), 115.41 (s, CH Ar), 50.22 (s, CH.sub.2 bridge), 46.42 (s, CH norb), 45.11 (s, CH norb), 42.89 (CHC?O norb), 41.10 (s, CH.sub.2NH), 35.67 (s, C.sub.ArCH.sub.2), 30.43 (s, CH.sub.2 norb); elementary analysis: calcd. for C.sub.16H.sub.19NO.sub.3. C-70.31, H-7.01, N-5.12, O-17.56; found: C-70.58, H-7.05, N-4.91, O-18.35.

Example 3Preparation of 5-norbornen-2-ylcarbonyloxymethylphosphonic acid (Phn-1C-Norb) (E3)

Step 1: Preparation of 5-norbornene-2-carboxylic acid chloride (Norb-Cl)

[0127] ##STR00033##

[0128] The synthesis known from literature was carried out as described in Chae et al., Macromolecules 51, 3458-3466 (2018) from 5-norbornene-2-carboxylic acid and oxalyl chloride in dry DCM in the presence of catalytic amounts of dimethyl formamide (DMF) to obtain the desired Norb-Cl by distillation as a colorless liquid.

[0129] 1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.32-6.17 (m, 1H, CH?CH endo/exo), 6.17-5.99 (m, 1H, CH?CH exo/endo), 3.49-2.71 (m, 3H, CH), 2.07-1.87 (m, 1H, CH.sub.2, CH.sub.2 bridge), 1.57-1.38 (m, 2H, CH.sub.2, CH.sub.2 bridge), 1.37-1.28 (m, 1H, CH.sub.2, CH?bridge); .sup.13C-NMR (101 MHZ, CDCB) ? (ppm): 175.19 (s, C?O). 139.17 (s, CH?CH exo), 138.83 (s, CH?CH endo), 135.02 (s, CH?CH exo), 131.75 (s, CH?CH endo). 56.56 (s, CHC?O endo), 56.45 (s, CHC?O exo), 49.36 (s, CH.sub.2 bridge), 47.29 (s, CH endo), 47.03 (s, CH exo), 46.43 (s, CH.sub.2 bridge), 43.00 (s, CH endo), 42.00 (s, CH exo), 31.29 (s, CH.sub.2 exo), 30.21 (s, CH.sub.2 endo).

Step 2: Preparation of 5-norbornen-2-ylcarbonyloxymethylphosphonic acid diethylester (PhnEt-1C-Norb)

[0130] ##STR00034##

[0131] Phosphonic acid diethyl(hydroxymethyl)ester PhnEt-1COH (1 eq., 2.2 ml, 15 mmol) was slowly (within 15 min) added to a mixture of Norb-Cl (1.5 eq., 3.5 g, 22.5 mmol) and triethylamine (TEA) (1.8 eq., 3.7 ml, 27 mmol) in 50 ml of dry DCM with stirring, then the reaction mixture was stirred at 0? C. for 1 h and at room temperature for 24 h. The solvent and the non-reacted educts were evaporated, and the raw product was again dissolved in 50 ml of DCM. The solution was washed with brine (3?25 ml), and the organic phase was dried over MgSO.sub.4. The solvent was evaporated, and the product was dried under vacuum to constant weight to obtain 4.3 g (99% of th.) of the desired PhnEt-1C-Norb as a brown viscous liquid.

[0132] DC (EE) R.sub.f=0.53; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.26-5.90 (m, 2H, CH?CH), 4.47-4.23 (m, 2H, PCH.sub.2O), 4.22-4.10 (m, 4H, OCH.sub.2CH.sub.3), 3.27-2.84 (m, 3H, 2?CH norb, CHC?O), 2.00-1.87 (m, 1H, CH.sub.2 norb), 1.57-1.23 (m, 9H, CH.sub.2 norb, CH.sub.2 bridge, 2?OCH.sub.2CH.sub.3); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 175.47 (s, exo C?O), 173.89 (s, endo C?O), 138.34 (s, exo CH?CH), 137.99 (s, endo CH?CH), 135.69 (s, exo CH?CH), 132.42 (s, endo CH?CH), 62.89-62.73 (m, OCH.sub.2CH.sub.3), 56.85 (d, .sup.1J.sub.CP=168.5 Hz, CH.sub.2P C.sub.1 endo), 56.61 (d, .sup.1J.sub.CP=168.7 Hz, CH.sub.2P C.sub.1 exo), 49.73 (s, CH.sub.2 bridge), 46.75 (s, exo CH norb), 46.44 (s, CH.sub.2 bridge), 45.89 (s, endo CH norb), 43.15 (s, endo CH norb), 42.93 (s, exo CH norb), 42.63 (s, endo CH norb), 41.77 (s, exo CH norb), 30.57 (s, exo CH.sub.2 norb), 29.51 (s, endo CH.sub.2 norb), 16.53 (d, .sup.3J.sub.CP=5.9 Hz, OCH.sub.2CH.sub.3); .sup.31P NMR (CDCl.sub.3) ? (ppm): 19.47; HR-MS (MeOH, ESI, m/z): calcd. 288.28, found 288.41 [M].

Step 3: Preparation of 5-norbornen-2-ylcarbonyloxymethylphosphonic acid (Phn-1C-Norb) (E3)

[0133] ##STR00035##

[0134] The synthesis was conducted in analogy to Synthesis Example 3, Step 2, from PhnEt-1C-Norb (1 eq., 5.2 g, 18 mmol) with TMSBr (3 eq., 6 ml, 45 mmol) to isolate 4.17 g (99% of th.) of the desired phosphonic acid Phn-1C-Norb as a brown viscous liquid. .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 8.17 (s, 2H), 6.23-5.87 (m, 2H, CH?CH), 4.51-4.27 (m, 2H, PCH.sub.2O), 3.30-3.14 (m, 1H, CH norb), 3.12-2.99 (m, 1H, CH norb), 2.97-2.87 (m, 1H, CHC?O), 2.01-1.86 (m, 1H, CH.sub.2 norb), 1.62-1.19 (m, 3H, CH.sub.2 norb, CH.sub.2 bridge); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 176.13 (s, exo C?O), 174.86 (s, endo C?O), 138.34 (s, exo CH?CH), 137.99 (s, endo CH?CH), 135.69 (s, exo CH?CH), 132.42 (s, endo CH?CH), 57.63 (d, .sup.1J.sub.CP=169.3 Hz, CH.sub.2P C.sub.1 exo), 56.96 (d, .sup.1J.sub.CP=169.2 Hz, CH.sub.2P C.sub.1 endo), 49.78 (s, CH.sub.2 bridge), 46.80 (s, exo CH norb), 46.48 (s, CH.sub.2 bridge), 46.03 (s, endo CH norb), 43.20 (s, endo CH norb), 42.99 (s, exo CH norb), 42.72 (s, endo CH norb), 41.79 (s, exo CH norb), 30.61 (s, exo CH.sub.2 norb), 29.51 (s, endo CH.sub.2 norb); .sup.31P NMR (CDCl.sub.3) ? (ppm): 20.93; HR-MS (MeOH, ESI, m/z): calcd. 288.28, found 288.28 [M].

Example 4Preparation of 6-(5-Norbornen-2-ylcarbonyloxy)hexylphosphonic acid (Phn-6C-Norb) (E4)

[0135] Step 1: Preparation of 6-(5-norbornen-2-ylcarbonyloxy)hexylphosphonic acid diethylester (PhnEt-6C-Norb)

##STR00036##

[0136] The synthesis was conducted in analogy to Example 3, Step 2, from phosphonic acid diethyl(6-hydroxyhexyl)ester PhnEt-6COH (1 eq., 2.9 g, 12 mmol) with Norb-Cl (2.5 eq., 4.7 g, 30 mmol) and TEA (2.8 eq., 4.7 ml, 33 mmol) in DCM to isolate, by column chromatography (PE:EE, 1:1), 3.01 g (70% of th.) of the desired ester PhnEt-6C-Norb as a brown viscous liquid.

[0137] DC (EE/MeOH, 19:1) R.sub.f=0.5; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.21-5.84 (m, 2H, CH?CH), 4.15-3.90 (m, 6H, OCH.sub.2CH.sub.3, CH.sub.2OC?O), 3.21-3.13+3.04-2.98 (m, 1H, CH norb), 2.95-2.81+2.25-2.13 (m, 2H, CH norb, CHC?O), 1.94-1.79 (m, 1H, CH.sub.2 norb), 1.77-1.52 (m, 5H, CH.sub.2 norb, CH.sub.2 bridge, CH.sub.2P), 1.44-1.20 (m, 14H, 2?OCH.sub.2CH.sub.3, 4?CH.sub.2 alkyl); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 176.37 (exo C?O), 174.87 (endo C?O), 138.12 (s, exo CH?CH), 137.83 (s, endo CH?CH), 135.85 (s, exo CH?CH), 132.42 (s, endo CH?CH), 64.28 (d, J=24.4 Hz, CH.sub.2OC?O), 61.50 (d, .sup.2J.sub.CP=6.5 Hz, OCH.sub.2CH.sub.3), 49.71 (s, CH.sub.2 bridge), 46.69 (s, exo CH norb), 46.44 (s, CH.sub.2 bridge), 45.80 (s, endo CH norb), 43.44 (s, endo CH norb), 43.28 (s, exo CH norb), 42.62 (s, endo CH norb), 41.71 (s, exo CH norb), 30.40 (s, exo CH.sub.2 norb), 30.27 (d, .sup.3J.sub.CP=17.0 Hz, CH.sub.2CH.sub.2CH.sub.2P C.sub.3), 29.27 (s, CH.sub.2CH.sub.2O C.sub.5), 28.53 (s, endo CH.sub.2 norb), 25.72 (d, .sup.1J.sub.CP=140.8 Hz, CH.sub.2P C.sub.1), 25.60 (d, .sup.4J.sub.CP=1.4 Hz, CH.sub.2 C.sub.4), 22.45 (d, .sup.2J.sub.CP=5.1 Hz, PCH.sub.2CH.sub.2 C.sub.2). 16.57 (d, .sup.3J.sub.CP=5.9 Hz, OCH.sub.2CH.sub.3); .sup.31P NMR (CDCl.sub.3) ? (ppm): 32.29.

Step 2: Preparation of 6-(5-Norbornen-2-ylcarbonyloxy)hexylphosphonic acid (Phn6C-Norb) (E4)

[0138] ##STR00037##

[0139] The synthesis was conducted in analogy to Synthesis Example 3, Step 2, from PhnEt-6C-Norb (1 eq., 2.9 g, 8 mmol) with TMSBr (2 eq., 2.1 ml, 16 mmol) to isolate 2.37 g (99% of th.) of the desired phosphonic acid Phn-6C-Norb as a brown viscous liquid. 1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 8.27 (s, 2H, OH), 6.24-5.84 (m, 2H, CH?CH), 4.12-3.95 (m, 2H, CH.sub.2OC?O alkyl), 3.24-3.14 (m, 1H, CH norb), 3.07-2.84 (m, 2H, CH norb, CHC?O), 2.25-2.15 (m, 1H, CH.sub.2 norb), 1.95-1.11 (m, 13H, CH.sub.2 norb, CH.sub.2 bridge, CH.sub.2P, 4?CH.sub.2 alkyl); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 176.60 (s, exo C?O), 175.15 (s, endo C?O), 138.17 (s, exo CH?CH), 137.92 (s, endo CH?CH), 135.90 (s, exo CH?CH), 132.46 (s, endo CH?CH), 64.39 (d, J=24.3 Hz, CH.sub.2OC?O), 49.77 (s, CH.sub.2 bridge), 46.75 (s, exo CH norb), 46.51 (s, CH.sub.2 bridge), 45.87 (s, endo CH norb), 43.52 (s, endo CH norb), 43.35 (s, exo CH norb), 42.67 (s, endo CH norb), 41.77 (s, exo CH norb), 30.48 (s, exo CH.sub.2 norb). 30.04 (d, .sup.3J.sub.CP=17.0 Hz, CH.sub.2CH.sub.2CH.sub.2P), 29.36 (s, CH.sub.2CH.sub.2O C.sub.5), 28.51 (s, endo CH.sub.2 norb), 25.54 (s, CH.sub.2 C.sub.4), 25.43 (d, .sup.1J.sub.CP=141 Hz, CH.sub.2P C.sub.1), 22.07 (d, .sup.2J.sub.CP=5.0 Hz, PCH.sub.2CH.sub.2 C.sub.2); .sup.31P NMR (CDC) ? (ppm): 36.87; HR-MS (MeOH, ESI, m/z): calcd. 302.35, found 302.35 [M].

Example 5Preparation of 6-(2,3-bis(5-norbornen-2-ylcarbonyloxy)propylthio)hexylphosphonic acid (Phn-6C-bisNorb) (E5)

Step 1: Preparation of 6-(2,3-dihydroxypropylthio)hexylphosphonic acid diethylester (PhnEt-6C-thioglyc)

[0140] ##STR00038##

[0141] The synthesis known from literature was carried out as described in Catel et al., Macromol. Mater. Eng. 300, 1010-1022 (2015) from hex-5-en-1-yl phosphonic acid diethylester (PhnEt-6C-Enyl) from Synthesis Example 9, Step 1, by addition of thioglycol in the presence of azobis(isobutyronitrile) (AlBN) in THF.

[0142] DC (EE/MeOH, 9:1) R.sub.f=0.9; RI n.sub.D.sup.20? C.: 1.4880; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 4.17-4.00 (m, 4H, OCH.sub.2CH.sub.3), 3.83-3.68 (m, 2H, CHOH, CH.sub.2OH), 3.63-3.54 (m, 1H, CH.sub.2OH), 2.71 (dd, .sup.2J.sub.HH=13.7, .sup.3J.sub.HH=5.0 Hz, 1H, SCH.sub.2CH), 2.62 (dd, .sup.2J.sub.HH=13.7, .sup.3J.sub.HH=7.8 Hz, 1H, SCH.sub.2CH), 2.56 (t, .sup.3J.sub.HH=7.4 Hz, 2H, CH.sub.2CH.sub.2S), 1.81-1.68 (m, 2H, PCH.sub.2), 1.68-1.54 (m, 4H, PCH.sub.2CH.sub.2, CH.sub.2CH.sub.2CH.sub.2S), 1.48-1.39 (m, 4H, PCH.sub.2CH.sub.2CH.sub.2, CH.sub.2CH.sub.2S), 1.33 (t, .sup.3J.sub.HH=7.1 Hz, 6H, OCH.sub.2CH.sub.3); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 70.32 (s, CHOH), 65.54 (s, CH.sub.2OH), 61.75 (d, .sup.3J.sub.CP=6.7 Hz, OCH.sub.2CH.sub.3), 35.78 (S. SCH.sub.2CH), 32.30 (s, CH.sub.2CH.sub.2S), 29.95 (d, .sup.3J.sub.CP=16.8 Hz, PCH.sub.2CH.sub.2CH.sub.2), 29.30 (s, CH.sub.2CH.sub.2CH.sub.2S), 28.11 (s, CH.sub.2CH.sub.2S), 26.64-24.44 (d, .sup.1J.sub.CP=140.8 Hz, PCH.sub.2), 22.21 (d, .sup.2J.sub.CP=5.1 Hz, PCH.sub.2CH.sub.2), 16.51 (d, .sup.3J.sub.CP=6.1 Hz, OCH.sub.2CH.sub.3); .sup.31P NMR (CDCl.sub.3) ? (ppm): 32.60.

Step 2: Preparation of 6-(2,3-bis(5-norbornen-2-ylcarbonyloxy)propylthio)hexylphosphonic acid diethylester (PhnEt-6C-bisNorb)

[0143] ##STR00039##

[0144] The synthesis was conducted in analogy to Example 3, Step 2, from PhnEt-6C-thioglyc (1 eq., 3.3 g, 10 mmol) with Norb-Cl (2.3 eq., 3.6 g, 23 mmol) and TEA (2.5 eq., 3.5 ml, 25 mmol) in dry DCM to isolate, by column chromatography (EE), 3.0 g (73% of th.) of the desired ester PhnEt-6C-bisNorb as a red viscous liquid.

[0145] DC (EE) R.sub.f=0.37; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.24-5.87 (m, 4H, 2?CH?CH), 5.23-4.98 (m, 1H, CHO), 4.46-4.15 (m, 2H, CH.sub.2O), 4.09 (m, 4H, OCH.sub.2CH.sub.3), 3.25-3.16 (m, 2H, 2?CH norb), 3.12-2.87 (m, 4H, 2?CH norb, SCH.sub.2CH), 2.74-2.62 (m, 2H, CH.sub.2SCH.sub.2 C.sub.5), 2.60-2.49 (m, 2H, CHC?O), 1.99-1.84 (m, 2H, CH.sub.2 norb), 1.79-1.22 (m, 22H, 2?CH.sub.2 bridge, 5?CH.sub.2 C.sub.1-C.sub.5, CH.sub.2 norb, 2?OCH.sub.2CH.sub.3); .sup.13C-NMR (101 MHz, CDCl.sub.3) ? (ppm): 174.14 (m, 2?C?O), 138.14 (s, CH?CH), 137.80 (s, CH?CH), 135.67 (s, CH?CH), 132.39 (s, CH?CH), 70.55-70.34 (m, CHO), 64.48-62.74 (m, CHCH.sub.2O), 61.42 (d, J=6.5 Hz, OCH.sub.2CH.sub.3), 49.64 (s, CH.sub.2 bridge), 46.35 (s, CH.sub.2 norb), 45.82-45.70 (m, CH norb), 43.42-43.25 (m, CHC?O), 42.59-42.49 (m, CH norb), 32.58 (s, SCH.sub.2CH), 32.34 (s, CH.sub.2SCH.sub.2), 30.18 (d, .sup.3J.sub.CP=17.0 Hz, PCH.sub.2CH.sub.2CH.sub.2), 29.24 (s, CH.sub.2CH.sub.2CH.sub.2S), 28.26 (s, CH.sub.2CH.sub.2S), 25.65 (d, .sup.1J.sub.CP=140.7 Hz, PCH.sub.2), 22.36 (d, .sup.2J.sub.CP=5.2 Hz, PCH.sub.2CH.sub.2), 16.52 (d, .sup.3J.sub.CP=6.0 Hz, OCH.sub.2CH.sub.3); .sup.31P NMR (CDCl.sub.3) ? (ppm): 32.34.

Step 3: Preparation of 6-(2,3-bis(5-norbornen-2-ylcarbonyloxy)propylthio)hexylphosphonic acid (Phn-6C-bisNorb) (E5)

[0146] ##STR00040##

[0147] The synthesis was conducted in analogy to Synthesis Example 3, Step 2, from PhnEt-6C-bisNorb (1 eq., 2.3 g, 4 mmol) with TMSBr (2.3 eq., 1.2 ml, 9.2 mmol) to isolate 1.86 g (91% of th.) of the desired phosphonic acid Phn-6C-bisNorb as a brown viscous liquid.

[0148] .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.24-5.86 (m, 4H, 2?CH?CH), 5.25-4.98 (m, 1H, CHO), 4.46-4.08 (m, 2H, CH.sub.2O), 3.26-3.14 (m, 2H, 2?CH norb), 3.12-2.87 (m, 4H, 2?CH norb, SCH.sub.2 CH), 2.77-2.63 (m, 2H, CH.sub.2SCH.sub.2 C.sub.6), 2.60-2.50 (m, 2H, CHC?O), CH.sub.2 norb), 1.99-1.21 (m, 18H, 2?CH.sub.2 bridge, 5?CH.sub.2 C.sub.1-C.sub.5, 2?CH.sub.2 norb); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 175.99-174.17 (m, 2?C?O), 138.28 (s, CH?CH), 137.99 (s, CH?CH), 135.79 (s, CH?CH), 132.47 (s, CH?CH), 70.80-70.39 (m, CHO), 64.19-63.51 (m, CHCH.sub.2O), 50.78 (s, CH.sub.2 norb), 49.74 (s, CH.sub.2 bridge), 45.82-45.70 (m, CH norb), 43.42-43.25 (m, CHC?O), 42.59-42.49 (m, CH norb), 32.64 (s, SCH.sub.2CH), 32.41 (s, CH.sub.2SCH.sub.2), 30.18 (d, .sup.3J.sub.CP=17.0 Hz, PCH.sub.2CH.sub.2CH.sub.2), 29.34 (s, CH.sub.2CH.sub.2CH.sub.2S), 28.25 (s, CH.sub.2CH.sub.2S), 25.58 (s, .sup.1J.sub.CP=140.9 Hz, PCH.sub.2, 22.08 (d, .sup.2J.sub.CP=5.2 Hz, PCH.sub.2CH.sub.2); .sup.31P NMR (CDCl.sub.3) ? (ppm): 36.46; HR-MS (MeOH, ESI, m/z): calcd. 512.62, found 512.62 [M].

Example 6Preparation of 6-(2,3-bis(5-norbornen-2-ylcarbonyloxy)propylthio)hexane-1,1-diyl-bis(phosphonic acid) (bisPhn-6C-bisNorb) (E6)

[0149] Step 1: Preparation of 6-(2,3-dihydroxypropylthio)hexane-1,1-diyl-bis(phosphonic acid diethylester) (bisPhnEt-6C-thioglyc)

##STR00041##

[0150] The synthesis known from literature was carried out as described in Catel et al., Macromol. Mater. Eng. 300, 1010-1022 (2015) from 6-(2,3-dihydroxypropylthio)hexylphosphonic acid diethylester (PhnEt-6C-thioglyc) by protecting the diol with 2,2-dimethoxypropane, then a second phosphonic acid diethylester group was introduced via diethyl chlorophosphite, followed by deprotection of the diol.

[0151] DC (EE) R.sub.f=0.18; .sup.1H NMR (400 MHz, CD.sub.3OD) ? (ppm): 4.23-4.11 (m, 8H, 4?OCH.sub.2 CH.sub.3), 3.75-3.67 (m, 1H, CHO), 3.59 (dd, .sup.3J.sub.HH=4.7 Hz, .sup.2J.sub.HH=11.2 Hz, 1H, CHCH.sub.2 O), 3.53 (dd, .sup.3J.sub.HH=5.8 Hz, .sup.2J.sub.HH=11.2 Hz, 1H, CHCH.sub.2O), 2.71 (dd, .sup.3J.sub.HH=5.7 Hz, .sup.2J.sub.HH=13.5 Hz, 1H, SCH.sub.2CH), 2.64-2.45 (m, 4H, P.sub.2CH C.sub.1+ CH.sub.2SCH.sub.2 C.sub.6+SCH.sub.2CH), 1.96-1.84 (m, 2H, CH.sub.2 C.sub.2), 1.61 (m, 4H, CH.sub.2CH.sub.2S C.sub.5, CH.sub.2 C.sub.4), 1.48-1.40 (m, 2H, CH.sub.2 C.sub.3), 1.35 (t, .sup.3J.sub.HH=7.1 Hz, 12H, 4?OCH.sub.2CHa); .sup.13C-NMR (101 MHZ, CD:OD) ? (ppm): 72.86 (s, CHCH.sub.2O), 65.96 (s, CHCH.sub.2O), 64.18 (d, .sup.2J.sub.CP=6.7 Hz, 4?OCH.sub.2CH.sub.3), 36.28 (1, .sup.1J.sub.CP=133.3 Hz, P.sub.2CH C.sub.1), 33.37 (s, SCH.sub.2CH), 30.31 (s, CH.sub.2SCH.sub.2 C.sub.6), 29.38 (s, CH.sub.2CH.sub.2CH.sub.2S C.sub.4), 25.39 (t, .sup.2J.sub.CP=5.0 Hz, P.sub.2CHCH.sub.2 C.sub.2), 16.74 (d, .sup.3J.sub.CP=6.0 Hz, 2?OCH.sub.2CH.sub.2), 16.70 (d, .sup.3J.sub.CP=6.0 Hz, 2?OCH.sub.2CH.sub.3); .sup.31P NMR (CD.sub.3OD) ? (ppm): 24.07.

Step 2: Preparation of 6-(2,3-bis(5-norbornen-2-ylcarbonyloxy)propylthio)hexane-1,1-diyl-bis(phosphonic acid diethylester) (bisPhnEt-6C-bisNorb)

[0152] ##STR00042##

[0153] The synthesis was conducted in analogy to Example 3, Step 2, from bisPhn-6C-thioglyc (1 eq., 9.9 g, 22 mmol) with Norb-Cl (2.5 eq., 8.6 g, 55 mmol) and TEA (2.8 eq., 6.2 g, 61.6 mmol) in dry DCM to isolate, by column chromatography (EE), 11.24 g (73% of th.) of the desired ester bisPhnEt-6C-bisNorb as a red viscous liquid.

[0154] DC (EE) R.sub.f=0.53; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.26-5.90 (m, 2H, CH?CH), 4.47-4.23 (m, 2H, PCH.sub.2O), 4.22-4.10 (m, 4H, OCH.sub.2CH.sub.3), 3.27-2.84 (m, 3H, 2?CH norb, CHC?O), 2.00-1.87 (m, 1H, CH.sub.2 norb), 1.57-1.23 (m, 9H, CH.sub.2 norb, CH.sub.2 bridge, 2?OCH.sub.2CH.sub.3); .sup.13C-NMR (101 MHz, CDCl.sub.3) ? (ppm): 175.47 (s, exo C?O), 173.89 (s, endo C?O), 138.34 (s, exo CH?CH), 137.99 (s, endo CH?CH), 135.69 (s, exo CH?CH), 132.42 (s, endo CH?CH), 62.89-62.73 (m, OCH.sub.2CH.sub.3), 56.85 (d, .sup.1J.sub.CP=168.5 Hz, CH.sub.2P C.sub.1 endo), 56.61 (d, .sup.1J.sub.CP=168.7 Hz, CH.sub.2P C: exo), 49.73 (s, CH.sub.2 bridge), 46.75 (s, exo CH norb), 46.44 (s, CH.sub.2 bridge), 45.89 (s, endo CH norb), 43.15 (s, endo CH norb), 42.93 (s, exo CH norb), 42.63 (s, endo CH norb), 41.77 (s, exo CH norb), 30.57 (s, exo CH.sub.2 norb), 29.51 (s, endo CH.sub.2 norb), 16.53 (d, .sup.3J.sub.CP=5.9 Hz, OCH.sub.2CH.sub.3); .sup.31P NMR (CDCl.sub.3) ? (ppm): 19.47; HR-MS (MeOH, ESI, m/z): calcd. 288.28, found 288.41 [M].

Step 3: Preparation of 6-(2,3-bis(5-norbornen-2-ylcarbonyloxy)propylthio)hexane-1,1-diyl-bis(phosphonic acid) (bisPhn-6C-bisNorb) (E6)

[0155] ##STR00043##

[0156] The synthesis was conducted in analogy to Synthesis Example 3, Step 2, from bisPhnEt-6C-bisNorb (1 eq., 10.6 g, 4 mmol) with TMSBr (2.3 eq., 1.2 ml, 9.2 mmol) to isolate 8.8 g (99% of th.) of the desired phosphonic acid bisPhn-6C-bisNorb as a deeply red viscous liquid.

[0157] .sup.1H NMR (400 MHZ, CD.sub.3OD) ? (ppm): 6.22-5.84 (m, 4H, 2?CH?CH), 5.22-4.94 (m, 1H, CHO), 4.51-4.23 (m, 1H, CH norb), 4.23-4.01 (m, 3H, CHCH.sub.2O, CH norb), 3.22-3.15 (m, 1H, CH norb), 3.10-2.84 (m, 4H, CH norb, SCH.sub.2CH), 2.75-2.60 (m, 2H, CH.sub.2CH.sub.2S), 2.60-2.49 (m, 2H, 2?CHC?O), 2.33 (tt, .sup.3J.sub.HH=24.2, .sup.2J.sub.HP=6.1 Hz, 1H, P.sub.2CHCH.sub.2), 2.28-2.13 (m, 2H, PCHCH.sub.2), 1.98-1.85 (m, 4H, 2?CH.sub.2 norb), 1.66-1.44 (m, 4H, 2?CH.sub.2 bridge norb), 1.44-1.34 (m, 4H, CH.sub.2CH.sub.2CH.sub.2S), 1.28-1.20 (m, 2H, PCHCH.sub.2CH.sub.2); .sup.13C-NMR (101 MHZ, CD.sub.3OD) ? (ppm): 176.00 (m, C?O), 174.36 (m, C?O), 138.42-138.14 (m, CH?CH), 138.03-137.75 (m, CH?CH), 135.76 (m, CH?CH), 132.64-132.26 (m, CH?CH), 71.24-70.21 (m, CHO), 63.93 (m, CHCH.sub.2O), 49.71 (s, CH.sub.2 bridge), 46.72 (s, CH.sub.2 norb), 46.49 (s, CH.sub.2 norb), 45.82 (m, CHC?O), 43.80-43.02 (m, CH norb), 42.62 (m, CH norb), 41.75 (m, CH norb), 37.94 (t, .sup.1J.sub.CP=128.7 Hz, P.sub.2CH), 32.90-32.13 (m, SCH.sub.2CH), 30.44 (s, CH.sub.2SCH.sub.2), 29.63-28.96 (m, CH.sub.2CH.sub.2S), 28.53 (t, .sup.3J.sub.CP=6.6 Hz, PCHCH.sub.2CH.sub.2), 28.30 (m, CH.sub.2CH.sub.2CH.sub.2S), 25.23 (1, .sup.2J.sub.CP=4.8 Hz, P.sub.2 CHCH.sub.2); .sup.31P NMR (CD:OD) ? (ppm): 22.73; HR-MS (MeOH, ESI, m/z): calcd. 592.58, found 592.58.

Example 7Preparation of 3-(3-(3,4-dihydroxyphenyl)propylthio)propane-1,2-diylbis(norbornen-2-carboxylate) (Catechol-3C-bisNorb) (E7)

Step 1: Preparation of 5-allyl-2,2-dimethyl-1,3-benzodioxol (Catechol.SUP.prot.-3C-Enyl)

[0158] ##STR00044##

[0159] A mixture of Catechol-3C-Enyl (1 eq., 9.8 ml, 57 mmol) from Synthesis Example 11, 2,2-dimethoxypropane (2 eq., 9.9 ml, 114 mmol), and p-toluenesulfonic acid (p-TsOH) (0.06 eq., 0.2 g, 1.14 mmol) in 350 ml of DCM was stirred at room temperature for 20 h, then the solution was washed with a saturated NaHCO.sub.3 solution (3?100 ml) and the aqueous layers with ethyl acetate (3?80 ml). The combined organic layers were dried over MgSO.sub.4 and concentrated to obtain 16.3 g (94% of th.) of the desired compound Catechol.sup.prot-3C-Enyl as a brown viscous liquid.

[0160] DC (PE) R.sub.f=0.27; .sup.1H NMR (400 MHZ. CDCl.sub.3) ? (ppm): 6.87-6.52 (m, 3H, CH Ar), 6.07-5.80 (m, 1H, CH.sub.2CH?CH.sub.2), 5.15-4.97 (m, 2H, CH.sub.2CH?CH.sub.2), 3.37-3.19 (m, 2H, CH.sub.2CH?CH.sub.2), 1.67 (s, 6H, CH.sub.3); .sup.13C-NMR (101 MHz, CDCl.sub.3) ? (ppm): 147.62 (s, CO), 145.77 (s, CO), 137.91 (s, CH?CH.sub.2), 133.35 (s, C.sub.qCH.sub.2CH), 120.77 (s, CH Ar), 115.7 (s, CH?CH.sub.2), 115.66 (s, C.sub.q(CH.sub.3).sub.2), 109.02 (s, CH Ar), 108.11 (s, CH Ar), 40.11 (s, C.sub.qCH.sub.2CH), 25.97 (s, C.sub.q(CH.sub.3).sub.2).

Step 2: Preparation of 3-(3-(2,2-dimethyl-1,3-benzodioxol-5-yl)propylthio)propane-1,2-diol (Catechol.SUP.prot.-3C-thioglyc)

[0161] ##STR00045##

[0162] Catechol.sup.prot-3C-Enyl (1 eq., 15 g, 79 mmol) and thioglycerol (1.5 eq., 12.8 g, 118.5 mmol) were dissolved in 250 ml of dry THF under argon. The mixture was degassed with argon form 45 min, then 0.2 g AIBN (0.02 eq., 0.92 mmol) were added and the reaction mixtures was stirred at 75? C. for 24 h while the reaction progress was monitored by DC and .sup.31P NMR. Subsequently, the solution was concentrated under reduced pressure, and the obtained raw product was purified by column chromatography (EE:PE, 50:50) to obtain 7.26 g (31% of th.) of the desired protected product Catechol.sup.prot-3C-thioglyc as a yellow viscous liquid.

[0163] DC (EE:PE 80:20) R.sub.f=0.54; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.71-6.48 (m, 3H, ArH), 3.87-3.63 (m, 2H, CH.sub.2OH), 3.63-3.42 (m, 1H, CHOH), 2.70-2.40 (m, 6H, C.sub.qCH.sub.2CH.sub.2CH.sub.2SCH.sub.2), 1.97-1.73 (m, 2H, C.sub.qCH.sub.2CH.sub.2), 1.65 (s, 6H, C.sub.q(CH.sub.3).sub.2); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 147.58 (s, CO), 145.74 (s, CO), 134.46 (s, C.sub.qCH.sub.2CH.sub.2), 120.67 (s, CH Ar), 117.72 (s, C.sub.q(CH.sub.3).sub.2), 108.74 (s, CH Ar), 108.07 (s, CH Ar), 70.02 (s, CHOH), 65.51 (s, CH.sub.2OH), 35.83 (SCH.sub.2CH), 34.55 (s, C.sub.q,ArCH.sub.2), 31.66 (s, C.sub.q,ArCH.sub.2CH.sub.2), 31.48 (s, CH.sub.2SCH.sub.2CH, 25.95 (s, C.sub.q(CH.sub.3).sub.2).

Step 3: Preparation of 3-(3-(2,2-dimethyl-1,3-benzodioxol-5-yl)propylthio)propane-1,2-diyl-bis(norbornen-2-carboxylate) (Catechol.SUP.prot.-3C-bisNorb)

[0164] ##STR00046##

[0165] The synthesis was conducted in analogy to Example 3, Step 2, from Catechol.sup.prot-3C-thioglyc (1 eq., 6.0 g, 20 mmol) with Norb-Cl (3 eq., 12.3 g, 60 mmol) and TEA (3.2 eq., 8.9 ml, 64 mmol) to isolate, by column chromatography (PE:EE 95:5), 4.5 g (42% of th.) of the desired protected product Catechol.sup.prot-3C-bisNorb as a brown viscous liquid.

[0166] DC (EE:PE, 1:9) R.sub.f=0.54; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.68-6.48 (m, 3H, 3?ArH), 6.23-5.86 (m, 4H, 2?CH?CH), 5.24-5.00 (m, 1H, CHO), 4.50-4.19 (m, 2H, CH.sub.2O), 3.28-2.86 (m, 4H, (m, 4?CH norb), 2.77-2.47 (m, 6H, C.sub.qCH.sub.2CH.sub.2CH.sub.2SCH.sub.2), 2.22 (m, 2H, 2?CHCO norb) 1.99-1.77 (m, 3H, CH.sub.2 norb, C.sub.qCH.sub.2CH.sub.2), 1.65 (s, 6H, C.sub.q(CH.sub.3).sub.2), 1.58-1.32 (m, 5H, CH.sub.2 norb, 2?CH.sub.2 bridge); .sup.13C-NMR (101 MHZ, CDCl.sub.3) ? (ppm): 175.81 (s, C?O), 175.48 (s, C?O), 147.54 (s, COC.sub.q), 145.69 (s, COC.sub.q), 138.21 (s, CH?CH), 135.74 (s, CH?CH), 134.52 (s, C.sub.qCH.sub.2CH.sub.2), 120.63 (s, CH Ar), 117.59 (s, C.sub.q(CH.sub.3).sub.2), 108.72 (s, CH Ar), 108.01 (s, CH Ar), 70.59 (s, CHO), 63.92 (s, CH.sub.2O), 49.69 (s, CH.sub.2 bridge), 46.45 (s, CH norb), 45.85 (s, CH norb), 43.51-43.10 (m, CHC?O norb), 42.82-42.42 (m, CH norb), 41.73 (s, CH norb), 34.48 (s, SCH.sub.2CH), 32.38 (s, Co.sub.q, ArCH.sub.2), 32.01 (s, CH.sub.2SCH.sub.2CH), 30.43 (s, CH.sub.2 norb), 29.31 (s, C.sub.q,ArCH.sub.2CH.sub.2), 25.91 (s, C.sub.q(CH.sub.3).sub.2).

Step 4: Preparation of 3-(3-(3,4-dihydroxyphenyl)propylthio)propane-1,2-diylbis(norbornen-2-carboxylate) (Catechol-3C-bisNorb) (E7)

[0167] ##STR00047##

[0168] A mixture of Catechol.sup.prot-3C-bisNorb (1 eq., 2.9 g, 5.4 mmol) and pyridinium-p-toluene-sulfonate PPTS (0.1 eq., 0.14 g, 0.54 mmol) in 30 ml of dry methanol was stirred under reflux overnight. The solvent was evaporated, and the raw product was dissolved in 50 ml of DCM. The organic layer was washed with NaHCO.sub.3 (3?75 ml) and dried over MgSO.sub.4 to isolate 1.73 g (64% of th.) of the desired product Catechol-3C-bisNorb as a brown viscous liquid.

[0169] DC (EE:PE, 1:1) R.sub.f=0.67; .sup.1H NMR (400 MHZ, CDCl.sub.3) ? (ppm): 6.91-6.51 (m, 3H, 3?ArH), 6.27-5.87 (m, 4H, 2?CH?CH), 5.25-5.06 (m, 1H, CHO), 4.59-4.33 (m, 1H, CH.sub.2O), 4.30-4.06 (m, 1H, CH.sub.2O), 3.27-2.86 (m, 4H, 4?CH norb), 2.83-2.41 (m, 6H, C.sub.qCH.sub.2CH.sub.2CH.sub.2SCH.sub.2), 2.40-2.16 (m, 2H, 2?CHCO norb), 2.03-1.73 (m, 3H, CH.sub.2 norb, C.sub.qCH.sub.2CH.sub.2), 1.57-1.33 (m, 5H, CH.sub.2 norb, 2?CH.sub.2 bridge); .sup.13C-NMR (101 MHz, CDCl.sub.3) ? (ppm): 176.47 (s, C?O), 175.09 (s, C?O), 143.63 (s, COC.sub.q), 142.35 (s, COC.sub.q), 138.28 (s, CH?CH), 135.74 (s, CH?CH), 133.77 (s, C.sub.qCH.sub.2CH.sub.2), 120.89 (s, CH Ar), 115.61 (s, CH Ar), 115.35 (s, CH Ar), 70.85 (s, CHO), 64.26 (s, CH.sub.2O), 49.76 (s, CH.sub.2 bridge), 46.68 (s, CH norb), 46.51 (s, CH.sub.2 bridge), 45.96 (s, CH norb), 43.53 (s, CHC?O norb), 43.44 (s, CHC?O norb), 43.27 (s, CH norb), 42.68 (s, CH norb), 41.75, 33.44 (SCH.sub.2CH), 32.58 (s, C.sub.q,ArCH.sub.2), 31.73 (s, CH.sub.2SCH.sub.2CH), 30.81 (s, 2?CH.sub.2 norb), 29.38 (s, C.sub.q,ArCH.sub.2CH.sub.2); elementary analysis: calcd. for C.sub.28H.sub.34O.sub.6S: C-67.44, H-6.87, O-19.25, S6.43, found: C-67.28, H-6.32, O-19.28, S-5.96.

Example 8Preparation of ethylenediaminetetraacetic acid-bis(2-(3,4-dihydroxyphenyl)ethyl)amide-bis(2-(5-norbornen-2-yl)ethyl)amide (bisCatechol-EDTA-bisNorb) (E8)

Step 1: Preparation of ethylenediaminetetraacetic acid dianhydride (EDTA dianhydride)

[0170] ##STR00048##

[0171] The synthesis known from literature was carried out as described in Peng et al., Org. Biomol. Chem. 15(30), 6441-6446 (2017) by reacting ethylenediaminetetraacetic acid (EDTA) with acetic acid anhydride in pyridine at 80? C.

[0172] DC (PE:EE, 2:1) R.sub.f=0.43; Fp.: 192-193?C; 1H NMR (400 MHZ, DMSO-d) ? (ppm): 3.71 (s, 8H, 4?(CH.sub.2).sub.2N), 2.66 (s, 4H, NCH.sub.2CH.sub.2N); .sup.13C-NMR (101 MHZ, DMSO-d) ? (ppm): 172.20 (s, 4?C?O), 54.71 (s, 4?(CH.sub.2).sub.2N), 51.37 (s, NCH.sub.2CH.sub.2N).

Step 2: Preparation of ethylenediaminetetraacetic acid-bis(2-(5-norbornen-2-yl)ethyl)amide (EDTA-bisNorb)

[0173] ##STR00049##

[0174] EDTA-dianhydride (1 eq., 4.6 g, 18 mmol) was dissolved in 46 ml of DMF and stirred for 10 min, then 5-norbornen-2-ylmethylamine (2.04 eq., 4.5 g, 36.7 mmol) was slowly added and the reaction mixture was stirred at 70? C. for 24 h. The brown mixture was concentrated, filtered, and treated with 13 ml of chloroform. Addition of 250 ml of diethylether (Et.sub.2O) led to the precipitation of a white solid, followed by removal of the supernatant. The precipitate was triturated twice with 150 ml of Et.sub.2O, removed by filtration and dried in vacuum to obtain 8.9 g (98% of th.) of the desired EDTA-diamide EDTA-bisNorb as a white solid.

[0175] Fp.: 148.1-153.2? ? C. (dec.); .sup.1H NMR (400 MHZ, DMSO-d) ? (ppm): 8.06-7.91 (m, 2H, 2?NH), 6.21-5.91 (m, 4H, 2?CH?CH), 3.35 (s, 4H, 2?NCH.sub.2COOH), 3.20 (s, 4H, 2?NHCOCH.sub.2), 2.88-2.81 (m, 2H, 2?CH.sub.2NH), 2.79-2.73 (m, 6H, 2?CH.sub.2NH, 4?CH norb), 2.71 (s, 4H, NCH.sub.2CH.sub.2N), 2.25-2.15 (m, 2H, 2?CHCH.sub.2NH norb), 1.81-1.70 (m, 2H, 2?CH.sub.2 norb), 1.36-1.27 (m, 2H, 2?CH.sub.2 norb), 1.25-1.02 (m, 4H, 2?CH.sub.2 bridge); .sup.13C-NMR (101 MHZ, DMSO-d) ? (ppm): 172.76 (s, 2?COOH), 170.07 (s, 2?NHC?O), 136.94 (s, 2?CH?CH), 132.57 (s, 2?CH?CH), 64.97 (s, 2?NCH.sub.2COOH), 57.81 (s, 2?NCH.sub.2C?O), 55.78 (s, NCH.sub.2CH.sub.2N), 52.50 (s, 2?CH.sub.2 bridge), 49.00 (s, 2?NHCH.sub.2CH), 43.73 (s, 2?CH norb), 41.91 (s, 2?CH norb), 38.47 (s, 2?CH norb), 29.76 (s, 2?CH.sub.2 norb); elementary analysis: calcd. for C.sub.26H.sub.38N.sub.4O.sub.6. C-62.13, H-7.62, N-11.15. O-19.10; found: C-62.23, H-7.78, N-10.57, O-19.01.

Step 3: Preparation of ethylenediaminetetraacetic acid-bis(2-(3,4-dihydroxyphenyl)ethyl)amide-bis(2-(5-norbornen-2-yl)ethyl)amide (bisCatechol-EDTA-bisNorb) (E8)

[0176] ##STR00050##

[0177] EDTA-bisNorb (1 eq., 7.5 g, 15 mmol), dopamine hydrochloride (5 eq., 11.5 g, 75 mmol) and DMAP (0.4 eq., 0.2 g, 6 mmol) were dissolved in 20 ml of DMF and stirred at ?10? ? C. under argon, then a suspension of EDC.Math.HCl in 70 ml of DMF was added dropwise while keeping the temperature under 0? C. After complete addition, the mixture was stirred at room temperature for 48 h, then the solvent was evaporated, the product was precipitated in deionized water, and the precipitate was dried under vacuum to obtain 8.3 g (72% of th.) of the desired EDTA-tetraamide bisCatechol-EDTA-bisNorb as a light brown solid.

[0178] Fp.: 112.3-116.5? C.; 1H NMR (400 MHZ, MeOD-d) ? (ppm): 7.90 (s, 2H, 2?NH norb), 6.79-6.75 (s, 2H, 2?NH dopa), 6.71-6.47 (m, 4H, 4?CH Ar), 6.48-6.34 (m, 2H, 2?CH Ar), 6.19-5.79 (m, 4H, 2?CH?CH), 3.52-3.44 (m, 2H, 2?CH.sub.2NH), 3.40 (t, .sup.3J.sub.HH=7.2 Hz, 4H, 2?NHCH.sub.2CH.sub.2 dopa), 3.35 (s, 8H, 4?NHCOCH.sub.2N), 3.26-3.06 (m, 2H, 2?CH.sub.2NH), 3.03-2.89 (m, 2H, CH.sub.2NH), 2.88 (s, 4H, NCH.sub.2CH.sub.2N), 2.84-2.76 (m, 4H, 4?CH norb), 2.67 (1, .sup.3J.sub.HH=7.2 Hz, 4H, 2?NHCH.sub.2CH.sub.2 dopa), 2.30-2.11 (m, 2H, 2?CHCH.sub.2NH norb), 1.91-1.81 (m, 2H, 2?CH.sub.2 norb), 1.49-1.27 (m, 2H, 2?CH.sub.2 norb), 1.25-1.07 (m, 4H, 2?CH.sub.2 bridge); .sup.13C-NMR (101 MHZ, MeOD-d) ? (ppm): 146.28 (s, 2?C.sub.qOH), 144.85 (s, 2?COH), 138.54 (s, 2?CH?CH), 133.32 (s, 2?CH?CH), 131.84 (s, 2?C.sub.qCH.sub.2CH.sub.2NH), 121.06 (s, CH Ar), 116.98 (s, CH Ar), 116.47 (s, CH Ar), 58.79 (s, NCH.sub.2C?O), 57.54 (s, NCH.sub.2C?O), 56.86 (s, NCH.sub.2C?O), 56.39 (s, NCH.sub.2C?O), 54.08 (s, NCH.sub.2CH.sub.2N), 49.66 (s, 2?CH.sub.2 bridge), 45.46 (s, CH norb), 44.75-44.32 (m, 2?NHCH.sub.2CH), 43.70 (s, CH norb), 42.37-41.43 (m, C.sub.qCH.sub.2CH.sub.2NH), 40.06-39.70 (m, CH norb), 36.03-35.45 (m, C.sub.qCH.sub.2CH.sub.2NH), 31.55-30.87 (m, 2?CH.sub.2 norb); elementary analysis: calcd. for C.sub.42H.sub.56N.sub.6O.sub.8: C-65.26. H-7.30, N-10.87, O-16.56; found: C-65.80, H-7.33, N-10.85, O-16.29.

Example 9Preparation of diethylenetriaminepentaacetic acid-bis(2-(5-norbornen-2-yl)ethyl)amide-tris(2-(3,4-dihydroxyphenyl)ethyl)amide (triCatechol-DTPA-bisNorb) (E9)

Step 1: Preparation of ethylenediaminetetraacetic acid dianhydride (DTPA-dianhydride)

[0179] ##STR00051##

[0180] The synthesis was conducted in analogy to Example 8, Step 1, according to the instructions in Peng et al., Org. Biomol. Chem. 15(30), 6441-6446 (2017) by reacting diethylenetriaminepentaacetic acid (DTPA) with acetic acid anhydride.

[0181] Fp.: 182.1-184.2? C.; 1H NMR (400 MHZ, DMSO-d) ? (ppm): 3.71 (s, 8H, 4?(CH.sub.2).sub.2N), 3.29 (s, 2H, NCH.sub.2COOH), 2.75 (t, .sup.3J.sub.HH=6.2 Hz, 4H, NCH.sub.2CH.sub.2N), 2.59 (t, .sup.3J.sub.HH=5.8 Hz, 4H, NCH.sub.2CH.sub.2N); .sup.13C-NMR (101 MHZ, DMSO-d) ? (ppm): 171.99 (s, CH.sub.2COOH), 165.81 (s, 4?C?O), 54.56 (s, CH.sub.2COOH), 52.61 (s, 4?NCH.sub.2COO), 51.79 (s, 2?NCH.sub.2CH.sub.2N), 50.74 (s, 2?NCH.sub.2CH.sub.2N).

Step 2: Preparation of diethylenetriaminepentaacetic acid-bis(2-(5-norbornen-2-yl)ethyl)amide (DTPA-bisNorb)

[0182] ##STR00052##

[0183] The synthesis was conducted in analogy to Example 8, Step 2, from DTPA dianhydride (1 eq., 23.4 g, 18 mmol) and 5-norbornen-2-ylmethylamine (2.04 eq., 4.5 g, 36.7 mmol) in 70 ml of DMF. The raw product was washed with 150 ml of DCM and 200 ml of Et.sub.2O and dried und vacuum to isolate 9.1 g (84% of th.) of the desired diamide DTPA-bisNorb as a brown solid.

[0184] Fp.: 83.5-87.6? C.; .sup.1H NMR (400 MHZ, DMSO-d) ? (ppm): 8.05 (t, .sup.3J.sub.HH=5.8 Hz, 2H, 2?NH), 6.18-5.93 (m, 4H, 2?CH?CH), 3.44 (s, 2H, NCH.sub.2COOH), 3.37 (s, 4H, 2?CHCH.sub.2NH), 3.23 (s, 4H, 2?COCH.sub.2N), 3.20-3.04 (m, 4H, 2?NHCOCH.sub.2), 2.99-2.94 (m, 4H, 2?NCH.sub.2CH.sub.2N), 2.89-2.81 (m, 4H, 2?NCH.sub.2CH.sub.2N), 2.78 (s, 2H, 2?CH norb), 2.75-2.67 (m, 2H, 2?CH norb), 2.26-2.17 (m, 2H, 2?CHCH.sub.2NH norb), 1.80-1.73 (m, 2H, 2?CH.sub.2 norb), 1.34-1.28 (m, 2H, 2?CH.sub.2 norb), 1.24-1.12 (m, 4H, 2?CH.sub.2 bridge); 1?C-NMR (101 MHZ, DMSO-d) ? (ppm): 172.75 (s, 2?CH.sub.2COOH), 171.99 (s, CH.sub.2COOH), 169.82 (s, 2?NHCOCH.sub.2N), 136.83 (s, 2?CH?CH), 132.62 (s, 2?CH?CH), 57.58 (s, 2?NCH.sub.2 COOH), 55.30 (s, NHCOCH.sub.2N), 54.92 (s, NCH.sub.2COOH), 52.27 (s, 2?NCH.sub.2CH.sub.2N), 51.09 (s, 2?NCH.sub.2CH.sub.2N), 48.95 (s, 2?CH.sub.2 bridge), 43.69 (s, 2?CH norb), 42.44 (s, 2?NHCH.sub.2CH), 41.88 (s, 2?CH norb), 38.39 (s, 2?CH norb), 29.74 (s, 2?CH.sub.2 norb); elementary analysis: calcd. for C.sub.30H.sub.45N.sub.5O.sub.8L C-59.68, H-7.51, N-11.60, O-21.20; found: C-59.58, H-7.46, N-11.69, O-21.35.

Step 3: Preparation of diethylenetriaminepentaacetic acid-bis(2-(5-norbornen-2-yl)ethyl)amide-tris(2-(3,4-dihydroxyphenyl)ethyl)amide (triCatechol-DTPA-bisNorb) (E9)

[0185] ##STR00053##

[0186] The synthesis was conducted in analogy to Example 8, Step 3, from DTPA-bisNorb (1 eq., 6.9 g, 11.5 mmol), dopamine hydrochloride (4 eq., 8.7 g, 46 mmol), and DMAP (0.6 eq., 0.8 g, 6.9 mmol) in 80 ml of DMF with a suspension of EDC.Math.HCl (3.5 eq., 7.7 g, 40.25 mmol) in 220 ml of DMF. The raw product was dissolved in ethanol and precipitated in deionized water to obtain 2.9 g (25% of th.) of a brown, highly viscous liquid. 1H NMR (400 MHZ, MeOD-d) ? (ppm): 7.88 (s, 2H, 2?NH norb), 6.89-6.26 (m, 9H, 9?CH Ar), 6.16-5.74 (m, 4H, 2?CH?CH), 3.59 (m, 2H, 2?CH.sub.2NH), 3.30 (t, .sup.3J.sub.HH=7.2 Hz, 6H, 3?NHCH.sub.2CH.sub.2 dopa), 3.16-2.93 (m, 12H, 5?NHCOCH.sub.2N), 3.04-2.95 (m, 2H, 2?CH.sub.2NH), 2.72-2.66 (m, 8H, 2?NCH.sub.2CH.sub.2N), 2.57 (t, .sup.3J.sub.HH=7.2 Hz, 6H, 3?NHCH.sub.2CH.sub.2 dopa), 2.25-2.12 (m, 2H, 2?CHCH.sub.2NH norb), 1.87-1.67 (m, 2H, 2?CH.sub.2 norb), 1.38-1.25 (m, 2H, 2?CH.sub.2 norb), 1.24-1.01 (m, 4H, 2?CH.sub.2 bridge); .sup.13C-NMR (101 MHZ, MeOD-d) ? (ppm): 173.22 (s, 3?NHCOCH.sub.2N dopa), 172.90 (s, 2?NHCOCH.sub.2N norb), 146.27 (s, 3?C.sub.qOH), 144.82 (s, 3?C.sub.qOH), 138.50 (s, 2?CH?CH), 133.35 (s, 2?CH?CH), 131.86 (s, 2?C.sub.qCH.sub.2CH.sub.2NH), 121.12 (s, 3?CH Ar), 117.00 (s, 3?CH Ar), 116.62 (s, 3?CH Ar), 59.78 (s, 3?NCH.sub.2C?O), 58.33 (s, NCH.sub.2CH.sub.2N), 56.46 (s, NCH.sub.2CH.sub.2N), 50.37 (s, 2?CH.sub.2 bridge), 45.49 (s, CH norb). 44.41 (m, 3?NHCH.sub.2CH), 43.69 (s, CH norb), 42.41-41.73 (m, C.sub.qCH.sub.2CH.sub.2NH), 39.97 (m, CH norb), 37.30 (m, CH norb), 36.01-35.28 (m, 3?C.sub.qCH.sub.2CH.sub.2NH), 31.14 (m, 2?CH.sub.2 norb); elementary analysis: calcd. for C.sub.54H.sub.72N.sub.8O.sub.11: C-64.27, H-7.19, N-11.10, O-17.44; found: C-64.27, H-7.86, N-11.64, O-18.27.

Examples 10 to 36, Comparative Examples 1 to 30Preparation and Testing of Polymerizable Compositions

Preparation of the Surfaces to be Coated

[0187] Three different substrates were prepared to measure the shear bond strength (SBS) of polymerizable compositions.

1) Hydroxyapatite

[0188] This mineral with the chemical formula Ca.sub.5[OH|(PO.sub.4).sub.3] represents the main component of the inorganic hard substance in bones and is therefore usually used as a model substance for test series with bone adhesives. For the purpose herein, hydroxyapatite (HAP) powder was obtained from Lithoz GmbH (Vienna, Austria) and cold-isostatically pressed into pellets with 400 kN for 1 min. The pellets thus obtained were then sintered in a laboratory oven from Carbolite Gero GmbH (Neuhausen, Germany) according to the following temperature program: with 2 K/min to 500? C. 30 min waiting time, with 2 K/min to 1250? C., 2 h waiting time, then cooling to room temperature with 3 K/min.

2) Titanium Dioxide

[0189] Titanium dioxide (TiO.sub.2) powder (? 200 nm) from Cinkarna (Celje, Slovenia) was lasers-intered to TiO.sub.2 pellets using a Hammer Lab35 Metal 3D Printer from Incus GmbH (Vienna, Austria).

3) Bovine Bones

[0190] For conducting ex-vivo measurements of bone material, parts of bovine hooves surrounding the distal end of the second phalanx, were cut into discs with a thickness of 1 cm with a band. The bovine toe bone discs were then cut into smaller pieces and placed in PBS buffer and frozen at ?80? C. for storage until use.

[0191] All three substrates were embedded in epoxy resin before coating with the polymerizable compositions, and their surfaces were polished smoothly with SiC wet sandpaper with a grain size of 400.

Preparation of the Polymerizable Compositions

[0192] By simply mixing one of the adhesion-providing primers prepared in the above Synthesis Examples and Examples with multifunctional monomers, multifunctional thiols and a standard radical initiator known from literature to be suitable for use in bone adhesives, one- and two-component compositions were prepared.

Examples 10 to 24, Comparative Examples 1 to 18Two-Component Compositions

[0193] To examine the tolerability of the new primers with regard to the other components of such compositions, several two-component compositions were initially prepared based on trimethylolpropane-tris(3-mercaptopropionate) (TMPMP) as the thiol and bis-(4-methoxybenzoyl)diethylgermanium, a radical photoinitiator commercially available under the trademark Ivocerin? from Ivoclar Vivadent (Schaan, Liechtenstein).

##STR00054##

[0194] Monomers examined where the trifunctional, relatively rigid triallylisocyanurate 1,3,3-triallyl-1,3,5-triazine-2,4,6-trione (TATATO) and the difunctional, biologically degradable vinyl ester O,O-(hexahydrofuro[3,2-b]furan-3,6-diyl)divinyladipate (glucitoldivinyl-adipate, GDVA).

##STR00055##

[0195] Mixtures of monomer, thiol, initiator, and primer were prepared as the first component and those without primer as the second component, herein referred to as primer formulation, PF, or matrix formulation, MF. The primer used was initially the common primer from Synthesis Example 1, 2,2-bis(allyloxymethyl)propanamido)methyl)phosphonic acid (BAPA.sup.Phn) (S1).

##STR00056##

[0196] The following Table 1 shows the amounts of the individual compounds in wt % based on the total mixture, wherein each formulation additionally contained 0.02 wt % of pyrogallol (1,2,3-trihydroxybenzene) as a thiol-ene stabilizer.

TABLE-US-00001 TABLE 1 First (PF) and second (MF) components of two-component compositions according to the state of the art with varying monomers BAPA.sup.Phn Monomer TMPMP Ivocerin Formulation [wt %] [wt %] [wt %] [wt %] PF1 15 12.5 TATATO 71 1.5 PF2 15 12.5 GDVA 71 1.5 MF1 32 TATATO 67 1 MF2 32 GDVA 67 1

[0197] From these four formulations, three combinations were mixed as two-component compositions and used for coating substrates, which coatings were then cured and examined for their shear bond strength: [0198] Comparative Example 1 (C1): PF1+MF1 [0199] Comparative Example 2 (C2): PF2+MF1 [0200] Comparative Example 3 (C3): PF1+MF2

[0201] For this purpose, hydroxyapatite or titanium dioxide discs prepared and polished as described above were first coated with the respective primer formulation PF by applying the mixture to the surface and scrubbing it for 20 s with a micro brush, letting it air-dry for 10 s, and then irradiating it for 10 s with a LED polymerization lamp Bluephase C8 by Ivoclar Vivadent (Schaan, Liechtenstein) with an emission in a wavelength range of 385-515 nm and a power of 720 mW cm-2. The respective matrix formulation MF was applied as the second component to the thus-cured first component (with the aid of a mold delimiting the edges of the surface in order to prevent the formulation from flow off), and cured by irradiation with the LED lamp for 20 s.

[0202] Then, the samples were placed in modified simulated body fluid (m-SBF) and stored for 24 h at 37? C., followed by an examination of the shear bond strength (SBS) of the cured composition using a VTSYIQI SF-30 digital force gauge with a V-shaped test rod.

[0203] As can be clearly seen from the results graphically show in FIG. 1A, from the three samples, only the combination of PF1 and MF1 of Comparative Example 1, where both components contained TATATO as monomer, showed good results in the shear bond strength test. Those of Comparative Examples 2 and 3, where only one of the two formulations used GDVA as the monomer, however, did not achieve even remotely satisfactory strength. Therefore, no tests with a combination of both GDVA-containing formulations, PF2+MF2, were performed.

[0204] Subsequently, the inventors performed a first polymerizable composition, wherein in analogy to the standard primer BAPA.sup.Phn examined before, one of the new primers with a similar spacer length and also two polymerizable groups PG and an adhesion motif AM was initially tested, namely 6-(2,3-bis(5-norbornen-2-ylcarbonyloxy)propylthio)hexylphosphonic acid (Phn-6C-bisNorb) (E5) from Example 5 with a phosphonic acid and two norbornenyl moieties:

##STR00057##

[0205] The preparation of formulations with the two monomers of TATATO and GDVA and Ivocerin as the initiator and their combination to obtain two-component compositions was also conducted in analogy to the above Comparative Examples 1 to 3, as specified below.

TABLE-US-00002 TABLE 2 First (PF) and second (MF) components of two-component compositions with varying monomers Phn-6C-bisNorb (E5) Monomer TMPMP Ivocerin Formulation [wt %] [wt %] [wt %] [wt %] PF1 15 12.5 TATATO 71 1.5 PF2 15 12.5 GDVA 71 1.5 MF1 32 TATATO 67 1 MF2 32 GDVA 67 1

[0206] These were again used to mix three combinations as two-component compositions: [0207] Example 10 (E10): PF1+MF1 [0208] Example 11 (E11): PF2+MF1 [0209] Example 12 (E12): PF1+MF2

[0210] These compositions were subsequently applied to the Example polished hydroxyapatite discs in the same way as described above, (pre)cured, and the shear bond strength of the coating was tested. The results are shown in FIG. 2A.

[0211] A comparison of the results of Comparative Examples 1 to 3 in FIG. 1A and of Examples 10 to 12 in FIG. 2A clearly shows that both GDVA-containing compositions of Examples 11 and 12 showed only insignificantly better values for the shear bond strength compared to those of Comparative Examples 2 and 3, however, the two-component composition of Example 1 without GDVA and with Phn-6C-bisNorb as the primer resulted in more than three times the shear bond strength compared to BAPA.sup.Phn in Comparative Example 1, namely 5.25?0.08 MPa according to the present invention compared to only 1.64?0.15 MPa according to the state of the art.

Variation of the Primer Concentration

[0212] Subsequently, the common primer BAPA.sup.Phn as well as Phn-6C-bisNorb (E5) were used in experiments with varying primer concentrations in the formulations. Here, in the above primer formulations PF1, each containing 15 wt % of primer, the amounts thereof were each reduced or increased by 5 wt % and the amounts of monomer (TATATO) and thiol (TMPMP) were also adapted correspondingly. These primer formulations, referred to, depending on the amount of primer, as PF10, PF15 and PF20, were each combined with the TATAO-containing matrix formulation MF1 to obtain two-component compositions. The exact compositions of the individual formulations are given in the overleaf Table 3.

TABLE-US-00003 TABLE 3 First (PF) and second (MF) components of two-component compositions according to the state of the art and in inventive uses with varying primer amounts BAPA.sup.Phn Phn-6C-bisNorb (E5) TATATO TMPMP Ivocerin Example Formulation [wt %] [wt %] [wt %] [wt %] [wt %] Comparative Example 1 (C1) PF.sub.15 15 12.5 71.0 1.5 Comparative Example 4 (C4) PF.sub.10 10 15.0 73.5 1.5 Comparative Example 5 (C5) PF.sub.20 20 10.0 68.5 1.5 Example 10 (E10) PF.sub.15 15 12.5 71.0 1.5 Example 13 (E13) PF.sub.10 10 15.0 73.5 1.5 Example 14 (E14) PF.sub.20 20 10.0 68.5 1.5 All foregoing examples MF1 32.0 67.0 1.0

[0213] The four new two-component compositions of Comparative Examples 4 and 5 as well as of Examples 13 and 14 were applied to hydroxyapatite surfaces in the same way as above, (pre)cured, and examined with regard to the shear bond strength of the coating. The results thus obtained are, together with those previously obtained for the compositions of Comparative Example 1 and Example 10 each containing 15 wt % of primer, shown in FIGS. 1B and 2B.

[0214] A comparison of these two diagrams again shows a similar trend for the comparative examples as well as the examples according to the present invention: In both cases, the new compositions resulted, with less (10 wt %) or more (20 wt %) of primer in the primer formulations, in a lower shear strength than before with 15 wt % of the respective primers each, wherein in each case, 10 wt % resulted in better values than 20 wt % of primer. Similar to the inventive Example 10 above with 15 wt % of Phn-6C-bisNorb in the primer formulation, Example 13 of the invention with 10 wt % of primer also shows a more than three times higher shear bond strength than the corresponding composition according to the state of the art with 10 or 15 wt % of BAPA.sup.Phn (3.62?0.09 MPa vs. 0.98?0.26 MPa). And for Example 14, the value is also more than twice as high as that of Comparative Example 5, each containing 20 wt % of primer (1.64?0.15 MPa vs. 0.75?0.21 MPa).

[0215] In summary, it can on the one hand be stated that a relatively rigid, trifunctional monomer like TATATO, which consequently has a stronger cross-linking effect, is clearly to be preferred over a difunctional and clearly more flexible monomer like GDVA. On the other hand, that approximately 15 wt % of primer in a primer formulation seem to be most suitable as the first component in a two-component composition to achieve high shear bond strengths of the cured compositions.

[0216] However, a content of 20 wt % and, in particular, only 10 wt % of primer also resulted in good or at least acceptable shear bond strengths, so that in general a content of 5 to 25 wt % of primer in the primer formulation of two-component compositions seem to be preferred, the content more preferably being approximately 7 wt % to approximately 17 wt %, in particular approximately 12 to 15 wt %.

Variation of the Thiol

[0217] Again using 15 wt % of primer in the primer formulation of a two-component composition, the thiol contained in the two components was then varied.

[0218] For this purpose, in both of the formulations PF and MF of Comparative Example 1 and Example 10 to be combined, the thiol TMPMP was replaced by the same amounts of either tris[2-(3-mercaptopropionyloxy)ethyl]isocyanurate (TEMPIC) or dipentaerythritol-hexakis(3-mercaptopropionate) (DiPETMP).

##STR00058##

[0219] The detailed compositions of the individual formulations are shown in the overleaf Table 4.

TABLE-US-00004 TABLE 4 First (PF) and second (MF) components of two-component compositions according to the state of the art and in inventive uses with varying thiols BAPA.sup.Phn Phn-6C-bisNorb TATATO TEMPMP TEMPIC DiPETMP Ivocerin Example Formulation [wt %] (E5) [wt %] [wt %] [wt %] [wt %] [wt %] [wt %] Comparative Example 1 (C1) PF1 15 12.5 71.0 1.5 Comparative Example 6 (C6) PF2 15 12.5 71.0 1.5 Comparative Example 7 (C7) PF3 15 12.5 71.0 1.5 Example 10 (E10) PF1 15 12.5 71.0 1.5 Example 15 (E15) PF2 15 12.5 71.0 1.5 Example 16 (E16) PF3 15 12.5 71.0 1.5 C1 and E10 MF1 32.0 67.0 1.0 C6 and E15 MF2 32.0 67.0 1.0 C7 and E16 MF3 32.0 67.0 1.0

[0220] The four new two-component compositions of Comparative Examples 6 and 7 as well as Examples 15 and 16 were applied on hydroxyapatite surfaces in the same way as above, (pre)cured, and the shear bond strength of the composition was examined. The results obtained are, together with the results previously obtained with the TMPMP-containing compositions of Comparative Example 1 and Example 1, shown in FIGS. 3A and 3B.

[0221] In FIG. 3 it is immediately noticeably that using DiPETMP as the thiol, according to the state of the art as well as in the inventive use, only very low shear bond strengths were achieved. Without wishing to be bound by theory, the inventors assume that this is, on the one hand, due to the high (or too high) degree of crosslinking achieved with the hexavalent thiol, so that only insufficient amounts of the phosphonic acid groups serving as adhesion motifs of the primers can contact the substrate surface and stay in contact with it. It is therefore to be assumed that with the use of strongly cross-linking thiols, such as DiPETMP, the use of a primer with a larger spacer chain length and/or a larger number of adhesion motifs AM will lead to better results.

[0222] However, while the replacement of the thiol of TMPMP with TEMPIC in experiments with BAPA.sup.Phn as the primer resulted in only a slight improvement of the values by approximately 5%, with the inventive use of the primer Phn-6C-bisNorb (E5) in Example 15, this replacement resulted in a more than 2 times higher shear bond strength compared to Example 1 (11.00?0.64 MPa vs. 5.25?0.08 MPa). Without wishing to be bound by this, the inventors attribute that, similar to the comparison between TATATO and GDVA as monomers, to the higher rigidity of TEMPIC compared to TMPMP.

[0223] Subsequently, a series of further comparative examples and examples for two-component compositions as combinations of TATATO as the monomer, TEMPIC as the thiol and Ivocerin as the initiator were prepared with the primers listed in the overleaf Tables 5 and 6.

TABLE-US-00005 TABLE 5 First (PF) and second (MF) components of two-component compositions according to the state of the art and in inventive uses with varying primers in the primer formulation PF as the first component Primer TATATO TEMPIC Ivocerin SBS HAP Example Formulation 15 wt % [wt %] [wt %] [wt %] [MPa] Comparative Example 6 (C6) PF BAPA.sup.Phn (S1) 12.5 71.0 1.5 1.8 Comparative Example 8 (C8) PF BAPA.sup.bisPhn (S2) * 11.5 70.0 1.5 3.9 Comparative Example 9 (C9) PF Phn-1C-Allo (S3) 12.5 71.0 1.5 3.1 Comparative Example 10 (C10) PF Phn-6C-Allo (S4) 12.5 71.0 1.5 3.5 Comparative Example 11 (C11) PF Phn-6C-bisAllo (S5) 12.5 71.0 1.5 5.2 Comparative Example 12 (C12) PF Phn-1C-Allcarb (S6) 12.5 71.0 1.5 2.7 Comparative Example 13 (C13) PF Phn-6C-Allcarb (S7) 12.5 71.0 1.5 3.1 Comparative Example 14 (C14) PF Phn-6C-bisAllcarb (S8) 12.5 71.0 1.5 4.1 Comparative Example 15 (C15) PF Phn-6C-Enyl (S9) * 11.5 70.0 1.5 2.9 Comparative Example 16 (016) PF Phn-11C-Enyl (S10) * 11.5 70.0 1.5 4.1 Example 15 (E15) PF Phn-6C-bisNorb (E5) 12.5 71.0 1.5 11.0 Example 17 (E17) PF Alendronate-Norb (E1) * 11.5 70.0 1.5 3.7 Example 18 (E18) PF Phn-1C-Norb (E3) 12.5 71.0 1.5 3.0 Example 19 (E19) PF Phn-6C-Norb (E4) 12.5 71.0 1.5 3.8 Example 20 (E20) PF bisPhn-6C-bisNorb (E6) * 12.5 71.0 1.5 6.8 All foregoing examples MF 32.0 67.0 1.0 * For improving solubility in the formulation, 1 wt % of water and 1 wt % of ethanol were added at the expense of the amount of monomer and thiol.

TABLE-US-00006 TABLE 6 First (PF) and second (MF) components of two-component compositions according to the state of the art and in inventive uses with varying primers in the primer formulation PF as the first component Primer TATATO TEMPIC Ivocerin SBS TIO.sub.2 Example Formulation 15 wt % [wt %] [wt %] [wt %] [MPa] Comparative Example 6 (C6) PF BAPA.sup.Phn (S1) 12.5 71.0 1.5 3.4 Comparative Example 8 (C8) PF BAPA.sup.bisPhn (S2) * 11.5 70.0 1.5 4.8 Comparative Example 9 (C9) PF Phn-1C-Allo (S3) 12.5 71.0 1.5 1.7 Comparative Example 10 (C10) PF Phn-6C-Allo (S4) 12.5 71.0 1.5 2.3 Comparative Example 11 (C11) PF Phn-6C-bisAllo (S5) 12.5 71.0 1.5 2.3 Comparative Example 12 (C12) PF Phn-1C-Allcarb (S6) 12.5 71.0 1.5 1.8 Comparative Example 13 (C13) PF Phn-6C-Allcarb (S7) 12.5 71.0 1.5 2.2 Comparative Example 14 (C14) PF Phn-6C-bisAllcarb (S8) 12.5 71.0 1.5 2.4 Comparative Example 15 (C15) PF Phn-6C-Enyl (S9) * 11.5 70.0 1.5 2.0 Comparative Example 16 C16) PF Phn-11C-Enyl (S10) * 11.5 70.0 1.5 2.3 Example 15 (E15) PF Phn-6C-bisNorb (E5) 12.5 71.0 1.5 7.9 Example 17 (E17) PF Alendronate-Norb (E1) * 11.5 70.0 1.5 7.5 Example 18 (E18) PF Phn-1C-Norb (E3) 12.5 71.0 1.5 2.8 Example 19 (E19) PF Phn-6C-Norb (E4) 12.5 71.0 1.5 2.7 Example 20 (E20) PF bisPhn-6C-bisNorb (E6) 12.5 71.0 1.5 4.5 All foregoing examples MF 32.0 67.0 1.0 * For improving solubility in the formulation, 1 wt % of water and 1 wt % of ethanol were added at the expense of the amount of monomer and thiol.

[0224] These new two-component compositions of Comparative Examples 8 to 16 and Examples 17 to 20 were applied to hydroxyapatite surfaces in the same way as above, but now alsojust like those of Comparative Example 6 and Example 15to titanium oxide surfaces, (pre-)cured, and the shear bond strength (SBS) of the individual coatings was examined. The results obtained are, together with the results previously obtained for Comparative Example 6 and Example 15, shown in Table 5 and FIG. 4 for hydroxyapatite (HAP) and in Table 6 and FIG. 5 for titanium dioxide (Ti).

[0225] From Table 5 and FIG. 4 it may be seen that primers with a chain length of the spacer between the polymerizable groups PG (vinyl, allyl or norbornenyl) and the adhesion motifs AM (here phosphonic acid groups throughout) with at least 6 carbon or hetero atoms on hydroxyapatite tend to result in better shear bond strengths than the shorter-chain spacers in Comparative Examples 15, 9, 12, and 6 and in Example 18 (Phn-1C-Norb). In addition, it was shown that primers with more than one PG and/or more than one AM also tend to show better results than those with only one corresponding moiety (i.e., in FIG. 4 all results left of the peak value for Example 15).

[0226] Furthermore, it is noticeable that the reference primer BAPA.sup.Phn from Comparative Example 6 showeddespite the presence of two allyl groups as PG and a spacer length of 6 atoms between the phosphonic acid moiety and each of the two allyl groups by far the worst result. In contrast, the measurements of Comparative Examples 11, 14 and 8, i.e., primers with 9 to 11 atoms between PG and AM, showed three times higher shear bond strengths, with the first two also containing only one AM and two allyl groups as PG, while BAPA.sup.bisPhen has an additional phosphonic acid moiety (HO).sub.2P(?O).

[0227] Nevertheless, in a direct comparison, the inventively used primers with norbornenyl as PG also showed better results than the three best primers according to the state of the art: Alendronate-Norb from Example 17 with only one PG and two AM showed approximately the same effectiveness as BAPA.sup.bisPhn with two PG and two AM and was hardly worse than Phn-6C-bisAllcarb with one AM and two allyl groups as PG. And Phn-6C-bisNorb from Example 15 as well as bisPhn-6C-bisNorb from Example 20 with two norbornenyl PG and one or two phosphonic acid moieties each resulted in clearly the best shear bond strengths SBS of the cured coatings on hydroxyapatite, while Phn6C-bisNorb from Example 15 with only one AM surprisingly showed even better results. Apparently, the inventors had from the very beginning coincidentally chosen the best of the new primers for their examinations.

[0228] With the experiments on titanium oxide surfaces, the situation was different. As can be seen in Table 6 and FIG. 5, again longer-chained spacers with at least 6 atoms between PG and AM moieties are to be preferred, however, in these cases, the two BAPA-containing primers of Comparative Examples 6 and 8 showed the best results of all primers according to the state of the art, with BAPA.sup.bisPhn having two AM and two PG again showing better shear bond strengths than BAPA.sup.Phn having only one phosphonic acid moiety. The primer bisPhn-6C-bisNorb from Example 20 with also two AM and two norbornenyl PG used according to the invention, however, is almost on a par with BAPA.sup.bisPhn, while Alendronate-Norb from Example 17 with only one Norb group and two AM, which had shown similar results as BAPA.sup.bisPhn on hydroxyapatite before, was now clearly superior and only superseded by Phn-6C-bisNorb with two norbornenyl PG and only one phosphonic acid AM from Example 15, which thus showed the best values.

[0229] However, the primers of Examples 18 and 19 with only one norbornenyl PG and one phosphonic acid moiety each showed better results on titanium oxide than all primers according to the state of the art, except for the two BAPA-containing onesand thus even better than the primers of Comparative Examples 11 and 14 with two allyl PG each; even though Phn-1C-Norb from Example 18 comprised a spacer with a chain length of only 3 atoms.

[0230] In summary, it can be stated that the inventive combinations of 5-norbornen-2-yl groups as polymerizable groups PG and phosphonic acid groups (HO).sub.2P(?O) as adhesion motifs AM in primers for polymerizable thiol-ene-based two-component compositions are clearly superior to those according to the state of the art. Apparently, the reactivity of the norbornenyl groups during polymerization of the primer formulation and the quick integration of the primer into the monomer matrix resulting therefrom are more prevalent here than the adhesive effect on the coated surface caused by the adhesion motif.

[0231] Subsequently, further two-component compositions were prepared using the previously prepared primers with pyrocatechol (or catechol) groups as adhesion motifs AM and examined with regard to the shear bond strength (SBS) of the coatings obtained therefrom in the same way as above, with the values for the BAPA-containing primers of Comparative Examples 6 and 8 and for the best primer Phn-6C-bisNorb from Example 15 used according to the invention also being listed for comparative purposes. The new pyrocatechol-containing primer compositions used were again combinations of TATATO as the monomer. TEMPIC as the thiol, and Ivocerin as the initiator, now prepared with the primers listed in the following Tables 7 and 8, with Comparative Example 18 being a literature value according to Olofsson et al., v.s. However, this value was not determined on hydroxyapatite, but on bones, namely with a two-component composition also containing TATATO as the monomer and TEMPIC as the thiol, but the initiator was not Ivocerin, but camphorquinone. The primer used was a 1:1 mixture of DOPA-Allyl and DOPA-Thiol:

##STR00059##

[0232] The results are also shown in Tables 7 and 8 and in FIGS. 6 and 7, while Example 21 with the primer catechol-2C-Norb (E2) when used on TiO.sub.2 surfaces (Table 8 and FIG. 7) known from the reference cited above, Ye et al., is to be seen as a comparative example. On the HAP surface (Table 7 and FIG. 6), which is to be seen as a model surface for the use as a bone adhesive, however, it is to be regarded an inventive example.

TABLE-US-00007 TABLE 7 First (PF) and second (MF) components of two-component compositions according to the state of the art and in inventive uses with varying primers in the primer formulation PF as the first component Primer TATATO TEMPIC Ivocerin SBS HAP Example Formulation 15 wt % [wt %] [wt %] [wt %] [MPa] Comparative Example 6 (C6) PF BAPA.sup.Phn (S1) 12.5 71.0 1.5 1.8 Comparative Example 8 (C8) PF BAPA.sup.bisPhn (S2) * 11.5 70.0 1.5 3.9 Comparative Example 17 (C17) PF Catechol-3C-Enyl (S11) * 11.5 70.0 1.5 1.5 Comparative Example 18 (C18) PF DOPA-Allyl + DOPA-Thiol ** 0.29 Example 15 (E15) PF Phn-6C-bisNorb (E5) 12.5 71.0 1.5 11.0 Example 21 (E21) PF Catechol-2C-Norb (E2) * 11.5 70.0 1.5 3.1 Example 22 (E22) PF Catechol-3C-bisNorb (E7) * 11.5 70.0 1.5 3.6 Example 23 (E23) PF bisCatechol-EDTA-bisNorb (E8) * 11.5 70.0 1.5 4.0 Example 24 (e24) PF triCatechol-DTPA-bisNorb (E9) * 11.5 70.0 1.5 0.4 Foregoing examples except C18 MF 32.0 67.0 1.0 Comparative Example 18 (C18) MF 32.1 67.8 0.1 *** * For improving solubility in the formulation, 1 wt % of water and 1 wt % of ethanol were added at the expense of the amount of monomer and thiol. ** SBS value from literature; Olofsson et al. (v.s.) *** Camphorquinone as the initiator

TABLE-US-00008 TABLE 8 First (PF) and second (MF) components of two-component compositions according to the state of the art and in inventive uses with varying primers in the primer formulation PF as the first component Primer TATATO TEMPIC Ivocerin SBS TIO.sub.2 Example Formulation 15 wt % [wt %] [wt %] [wt %] [MPa] Comparative Example 6 (C6) PF BAPA.sup.Phn (S1) 12.5 71.0 1.5 3.4 Comparative Example 8 (C8) PF BAPA.sup.bisPhn (S2) * 11.5 70.0 1.5 4.8 Comparative Example 17 (C17) PF Catechol-3C-Enyl (S11) * 11.5 70.0 1.5 1.1 Example 15 (E15) PF Phn-6C-bisNorb (E5) 12.5 71.0 1.5 7.9 Example 21 (E21); here a PF Catechol-2C-Norb (E2) * 11.5 70.0 1.5 0.9 comparative example Example 22 (E22) PF Catechol-3C-bisNorb (E7) * 11.5 70.0 1.5 1.1 Example 23 (E23) PF bisCatechol-EDTA-bisNorb (ES) * 11.5 70.0 1.5 5.3 Example 24 (E24) PF triCatechol-DTPA-bisNorb (E9) * 11.5 70.0 1.5 0.5 All foregoing examples MF 32.0 67.0 1.0 * For improving solubility in the formulation, 1 wt % of water and 1 wt % of ethanol were added at the expense of the amount of monomer and thiol.

[0233] From the SBS results in Table 7 and FIG. 6 it is noticeable that the inventively used primer triCatechol-DTPA-bisNorb from Example 24 had resulted in a shear bond strength that was only slightly better than the value cited in literature for the mixture of DOPA-Allyl and DOPA-Thiol, but significantly worse than the other values for pyrocatechol-containing primers. However, this is partly due to the fact that these are weight-related primer portions in the formulations, as well as the fact that the three inventively used primers of Examples 21 to 23 did not show better results than the extremely short-chained primer from Comparative Example 17 with a spacer length of only one single carbon atom. Taking into account the highly different molecular weights, the primer formulations of Examples 21 to 24 contained only about half (E21), one third (E22), one fifth (E23), or one seventh (E24) of the molecular amount of primer in Comparative Example 17 (Catechol-3C-Enyl). However, the comparatively bad value of Example 24 is, according to the opinion of the inventors, probably due to the fact that this triCatechol-DTPA-bisNorb primer was not completely soluble in the monomer/thiol mixture, despite the addition of water and ethanol. Further tests with this primer are, therefore, the subject of further investigations by the inventors.

[0234] The effectiveness of the three inventively used primers of Examples 21 to 23 or 22 and 23 is, however, to be estimated much higher than reflected by the values in Table 8 and the graph in FIG. 6 because of the high differences in molecular weight compared to those of Comparative Example 17, but also to the two BAPA-containing primers of Comparative Examples 6 and 8. Of course, this also applies to the above examples with phosphonic acid moieties as adhesion motifs.

[0235] In a direct comparison between the primers with two polymerizable groups PG and one adhesion motif AM, i.e., Catechol-3C-bisNorb (E22) and BAPA.sup.Phn (C6), the inventively used primer achieved a shear bond strength value twice as high. In a comparison between the primers with two PG and two AM each, i.e., bisCatechol-EDTA-bisNorb (from E23) and BAPA.sup.bisPhn (from C8), the inventively used primer only shows slightly better results, however, this is one the one hand again due to its higher molecular weight and on the other hand to the fact that phosphonic acid groups on hydroxyapatite surfaces are more effective adhesion motifs than pyrocatechyl residues, as is clearly shown by the peak value of the primer from Example 15 shown here again for comparative purposes. It is approximately three times higher than that of Example 22, even though both primers are structured analogously (2 PG and 1 AM each) and have comparable molecular weights. In particular, this last effect has a stronger impact on titanium oxide surfaces, as is shown by the values in Table 8 and the graph in FIG. 7. Here, the peak value of pyrocatechol the inventively used primer from Example 15 is even approximately seven times higher than that from Example 22, which means that phosphonic acid groups are to be preferred as AM especially on titanium oxide. Without wishing to be bound by this, the inventors assume that this might partly be due to a certain inhibiting effect of the phenolic OH groups during radical polymerization.

[0236] In addition to the, again due to the solubility, bad value for the triCatechol-DTPA-bisNorb primer from Example 24, it is noticeable in this case that the inventively used primer from Example 23 with two norbonenyl PG and two Pyrocatechyl AM shows better results here compared to the peak value of Example 14 than before on hydroxyapatite, which again proves the inventive preference of at least two norbornenyl groups as PG and at least two phosphonic acid or pyrocatechyl groups as AM. Also, the value for Example 23 is in this case even 10% better than that for the BAPA primer with an analogous structure from Comparative Example 8even though the latter has two phosphonic acid PG that provide stronger adhesion than the two pyrocatechyl groups of bisCatechol-EDTA-bisNorb from Example 23.

Examples 25 to 36, Comparative Examples 19 to 30One-Component Compositions

[0237] In analogy to above, this group of examples comprised the preparation of one-component compositions by mixing monomers, thiols, initator, and one primer used according to the invention or according to the state of the art each, applying it to a polished substrate surface made of hydroxyapatite or titanium dioxide, irradiated for 20 s and thus cured, placed in modified simulated body liquid, stored for 24 h at 37? C., and then tested with regard to the shear bond strength (SBS) of the cured coating using the VTSYIQI SF-30 digital force gauge with a V-shaped test rod.

[0238] All formulations of the one-component compositions contained a monomer TATATO (27.0 wt %), a thiol TEMPIC (57.0 wt %) and Ivocerin (1.0 wt %) as the initiator. The primers used were exclusively phosphonic acid groups as AM-containing compounds (15 wt %). Table 9 shows the formulations thus prepared, which again each contained additionally 0.02 wt % of pyrogallol as an oxidation stabilizer, as well as the shear bond strength values on hydroxyapatite (HAP) and titanium dioxide (TiO.sub.2) surfaces thus obtained, these values being also graphically shown in FIG. 8 and FIG. 9, respectively.

TABLE-US-00009 TABLE 9 One-component compositions according to the state of the art and according to the present invention with varying primers SBS HAP SBS TiO.sub.2 Example Primer [MPa] [MPa] Comparative BAPA.sup.Phn (S1) 8.1 4.1 Example 19 (C19) Comparative BAPA.sup.bisPhn (S2) * 1.0 1.1 Example 20 (C20) Comparative Phn-1C-Allo (S3) 1.6 1.8 Example 21 (C21) Comparative Phn-6C-Allo (S4) 3.6 2.8 Example 22 (C22) Comparative Phn-6C-bisAllo (S5) 3.5 2.2 Example 23 (C23) Comparative Phn-1C-Allcarb (S6) 1.8 1.8 Example 24 (C24) Comparative Phn-6C-Allcarb (S7) 3.6 2.7 Example 25 (C25) Comparative Phn-6C-bisAllcarb (S8) 3.5 2.1 Example 26 (C26) Example 25 (E25) Phn-1C-Norb (E3) ** 0.0 0.0 Example 26 (E26) Phn-6C-Norb (E4) 8.0 3.6 Example 27 (E27) Phn-6C-bisNorb (E5) 15.4 8.0 Example 28 (E28) bisPhn-6C-bisNorb (E6) * 0.5 1.8 Example 29 (E29) Alendronate-Norb (E1) * 1.1 0.8 *: not completely soluble **: discoloration

[0239] The primers marked with * were not completely soluble in the formulations, and the primer marked with ** from Example 25 led to a strong brown discoloration of the formulation, which greatly hindered the penetration of the radiation during exposure and significantly reduced the curing depth, so that almost no adhesion to the substrate was noticeable. Further tests with these primers, also with the addition of H.sub.2O and ethanol again to improve solubility, are therefore subject of current investigations conducted by the inventors.

[0240] As can be seen from Table 9 and FIG. 8, however, the other two inventively used primers of Examples 26 and 27, which did not show any problems, were again superior to those of the comparative examples, of which BAPA.sup.Phn (S1) from Comparative Example 19 showed by far the best results because it had achieved more than twice the shear bond strength of all other comparative primers. Phn-6C-Norb (E4) from Example 26 on hydroxyapatite (HAP) still resulted in almost the same shear bond strength value, even though this new primer contains only one polymerizable norbornenyl group, while BAPA.sup.Phn (S1) has two allyl groups. The best primer according to the invention was, as expected, again Phn-6C-bisNorb (E5) from Example 27 with an analogous structure to BAPA.sup.Phn (S1) and two norbornenyl groups and a phosphonic acid group as the adhesion motif, which even reached a shear bond strength value almost twice as high as that of BAPA.sup.Phn (S1)on hydroxyapatite as well as on titanium dioxide, as can be seen in FIG. 9. Also on TiO.sub.2, the primer from Example 26 with only one polymerizable group showed better results than all comparative primers except BAPA.sup.Phn (S1), the value of which was approximately 10% higher here.

[0241] Subsequently, the three primers of BAPA.sup.Phn (S1), Phn-6C-Norb (E4), and Phn-6C-bisNorb (E5) were also tested on the bovine toe bone discs prepared as described above in the form of analogous one-component compositions that, in addition to 15 wt % of primer, again contained 27.0 wt % of TATATO as the monomer, 57.0 wt % of TEMPIC as the thiol, and 1.0 wt % of Ivocerin as the initiator. Application, curing, and measuring were conducted as above. Furthermore, the best inventively used primer, Phn-6C-bisNorb (E5), was tested for a second time on such a bone disc, wherein, however, the disc was wetted before application by rubbing in distilled water with a micro brush for 20 s and then letting it air-dry for 10 s. The composition of the formulations and the results obtained therewith are shown in the following Table 10, and the latter are also graphically shown in FIG. 10.

TABLE-US-00010 TABLE 10 One-component composition according to the state of the art and according to the present invention on bovine bones SBS Bones Example Primer [MPa] Comparative BAPA.sup.Phn (S1) 2.4 Example 27 (C27) Example 30 (E30) Phn-6C-Norb (E4) 2.5 Example 31 (E31) Phn-6C-bisNorb (E5) 9.6 Example 32 (E32) Phn-6C-bisNorb (E5) ** 9.6 **: wetted bones

[0242] The ratio of the measured values was, as expected, similar to the previous ones on hydroxyapatite, which is used as a model substance for experiments with bone adhesives, even though the shear strength on smoothly polished, homogeneous hydroxyapatite surfaces was comprehensibly higher than on bone discs. However, the two inventively used primers on bone material exceeded the known primer BAPA.sup.Phn (S1) from Comparative Example 27 even more clearly than before. In this case, the shear bond strength value achieved with Phn-6C-Norb (E4) in Example 30 was even slightly higher than the comparative value for the primer with two polymerizable groups, however, that for the primer Phn-6C-bisNorb (E5) with an analogous structure was even almost five times as high as that of the comparisonon dry (Example 31) as well as on pre-wetted and shortly dried bovine bones (Example 32).

[0243] The following Table 11 again shows the results for the best inventively used primer, Phn-6C-bisNorb (E5), and the comparative primer BAPA.sup.Phn (S1) with an analogous structure on all three tested surfaces, bovine bones (bones), hydroxyapatite (HAP), and titanium dioxide (Ti), additionally including, as comparative examples, literature values for BAPA.sup.Phn (from Granskog et al., v.s.) as well as the bone adhesives and cements mentioned at the beginning and available under the trademarks OsStic? by PBC Biomed and Tetranite? by LaunchPad Medical (from Pujari-Palmer et al., v.s.; and Kirillova et al., v.s., respectively), each on hydroxyapatite surfaces. FIG. 11 is a graphic representation of these values.

TABLE-US-00011 TABLE 11 One-component compositions according to the state of the art and used according to the invention SBS B SBS HAP SBS TiO.sub.2 Example Primer [MPa] [MPa] [MPa] Comparative BAPA.sup.Phn (S1) 2.4 Example 27 (C27) Comparative BAPA.sup.Phn (S1) 8.1 4.1 Example 19 (C19) Comparative BAPA.sup.Phn ** 1.2 Example 28 (C28) Comparative OsStic? *** 1.5 Example 29 (C29) Comparative Tetranite? **** 1.9 3.3 Example 30 (C30) Example 31 (E31) Phn-6C-bisNorb (E5) 9.6 Example 27 (E27) Phn-6C-bisNorb (E5) 15.4 8.0 **: Granskog et al. (v.s.) ***: Pujari-Palmer et al. (v.s.) ****: Kirillova et al. (v.s.)

[0244] One-component compositions with the best primer according to the present invention, Phn-6C-bisNorb (E5), thus show significantly better results than previously known systems on all tested surfaces. Due to the generally higher shear strength on hydroxyapatite surfaces than on bone discs, as mentioned above, significantly lower values than those given in the literature for hydroxyapatite are to be expected for the known systems from Comparative Examples 28 to 30 on bovine bones, but probably also on titanium dioxide surfaces.

[0245] Finally, the inventors also conducted experiments with filled one-component compositions using Phn-6C-bisNorb (E5), wherein the formulation again containing 15 wt % of the primer, 27.0 wt % of TATATO, 57.0 wt % of TEMPIC, and 1.0 wt % of Ivocerin was mixed with different amounts of hydroxyapatite or titanium dioxide as a filler.

[0246] In order to avoid problems with regard to the penetration depth of radiation, the fillers were functionalized with the inventively used bis(phosphonic acid) primer, bisPhn-6C-bisNorb (E6). Here, 4 g of each filler powder were dispersed with 0.5 g of the primer in 10 ml of MeOH:H.sub.2O (1:4 Vol.), stirred for 24 h, filtered, washed with MeOH (3?50 ml), and dried under high vacuum. The fillers thus functionalized were each mixed in the given parts by weight based on 100 parts by weight of the formulation. The respective compositions and the results obtained therewith on the different surfaces (bones, B, hydroxyapatite, HAP, and titanium dioxide, TiO.sub.2) are shown in the following Table 12, wherein the latter are also graphically shown in FIG. 12. Table 12 also again includes the values of the comparative examples with BAPA.sup.Phn as the primer without filler.

TABLE-US-00012 TABLE 12 Filled one-component compositions used according to the invention with Phn-6C-bisNorb (E5) as the primer SBS Filler SBS B SBS HAP TiO.sub.2 Example (parts by weight) [MPa] [MPa] [MPa] Comparative 2.4 Example 27 (C27) Comparative 8.1 4.1 Example 19 (C19) Example 31 (E31) 9.6 Example 27 (E27) 15.4 8.0 Example 33 (E33) Hydroxyapatite (25) 7.9 5.2 4.5 Example 34 (E34) Hydroxyapatite (50) 7.0 5.6 4.2 Example 35 (E35) Titanium dioxide (25) 5.2 6.7 5.5 Example 36 (E36) Titanium dioxide (50) 5.0 6.3 5.2

[0247] This shows that the shear bond strengths obtained with the filled formulations are reduced compared to the respective unfilled examples, however, they were superior to the values of the unfilled comparative examples with BAPA.sup.Phn as the primer on bovine bones and titanium dioxide. Assuming a similar reduction of the shear bond strength of the comparative examples with a corresponding addition of a filler, i.e., by a factor of approximately 2.5 to 3, the inventive examples would almost certainly also supersede those with BAPA.sup.Phn as the primer on hydroxyapatite. Corresponding experiments are subject of current investigations by the inventors.

[0248] The above examples and comparative examples thus impressively demonstrate the superiority of the primers and of the thiol-ene-based polymerizable compositions containing the same when used according to the present invention compared to the state of the art.